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GeNerAl iNtroductioN
Fistula is the Latin word for a reed, pipe or flute. In medicine a fistula is defined as an 
abnormal communication between two epithelium lined surfaces. Anal fistulas are 
abnormal communications between the anal canal and the perianal skin or perineum. 
They are associated with considerable discomfort and morbidity and patients will 
frequently have cyclic periods in which the external fistula opening temporarily closes 
causing pain and swelling until the external fistula opening opens again leading to 
release of purulent material or blood. The incidence of anal fistulas varies between 
0.86 and 2.32 per 10.000/year,1,2 there is a male predominance with ratios varying 
from 2:1 to 5:1 1, 3-5 and most patients are between 30 and 50 years old.1 Overall anal 
fistulas are considered to be a discomforting disease that require adequate treatment.
ANAtomy
A thorough understanding of the anorectal anatomy is essential for classification and 
treatment of anal fistulas. The rectum begins at the level of the promontorium and in 
general follows along the curvature of the sacrum and coccyx for its entire length. As 
the rectum passes through the pelvic diaphragm at the level of the anorectal ring it 
becomes the anal canal and extends for 2 to 5 centimeters in length. The upper two 
third of the anal canal is lined by simple columnar epithelium and the lower one third 
of the anal canal is lined by stratified squamous epithelium. The dentate line divides 
both and is defined by the anal columns. At this level the ducts of the anal glands 
flow into the anal crypts. More than one anal gland may open into the same crypt 
and 30 to 50% of the anal glands branch out into the intersphincteric space. The 
number of anal glands is higher in men than women. Immunohistochemical staining 
methods have shown presence of mucous secreting cells and intraluminal secretions 
in these glands.6 However, it remains controversial whether these glands have an 
active secretory function.
The anal canal is surrounded by the internal and external anal sphincter muscle 
and they are considered to be essential for fecal continence. Both anal sphincter are 
equally thick between sexes. However, in women the anterior part of the external 
anal sphincter is shorter. The internal anal sphincter consists of smooth muscle and is 
innervated by the autonomic nervous system while the external anal sphincter consists 
of striated skeletal muscle and has somatic innervation. At the upper level the external 
anal sphincter becomes continuous with the puborectal muscle, which forms a sling 
behind the anal canal and is attached to the pubic bone. The puborectal muscle is part 
of the levator ani muscle, a broad thin muscle that forms the pelvic floor. Both the 
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high-pressure zone in the anal canal and the angulation between the rectum and anal 
canal, which is a result of the tonic contraction of the puborectal muscle, contribute 
to fecal continence. Both anal sphincters are responsible for the anal high-pressure 
zone at rest, however the internal anal sphincter supplies the largest contribution to 
this anal resting pressure.
etioloGy ANd PAthoGeNesis
Anal fistulas are the result of an infection. Anorectal infections can be classified as 
specific or nonspecific. Specific causes for anal fistulas involve identifiable primary dis-
eases, such as Crohn’s disease, or specific mechanism, such as iatrogenic or obstetric 
trauma. These specific causes are not the focus of this thesis. The way nonspecific 
anorectal infections cause anal fistulas is described by the cryptoglandular hypoth-
esis.7-12 Although it is impossible to prove this hypothesis, it is generally accepted 
by surgeons. The cryptoglandular hypothesis states that anal fistulas arise from anal 
glands. Anal glands flow into the anal crypts and drain into the anal canal. If these 
glands become blocked, stasis occurs and infection develops. Because 30 to 50% of 
the anal glands extend into the intersphincteric space, infection can pass the internal 
anal sphincter that serves as a barrier against contamination. Less well known is that in 
1967 Goligher and colleagues challenged the cryptoglandular hypothesis.13 In a series 
of 29 patients with an acute perianal abscess, only five showed communication with 
the crypt region, supporting the argument that in about two-thirds of the anorectal 
infections the cryptoglandular etiology does not apply. Studies on the etiology of anal 
fistulas are rare and therefore more studies are needed to understand it completely.
Anorectal infection can follow two routes, 1. Downward or upward between the 
internal and external anal sphincter; 2. Through the external anal sphincter by a 
transsphincteric or extrasphincteric tract. From these two routes four types of anal 
abscesses may develop, 1. Perianal; 2. Intersphincteric; 3. Ischioanal; 4. Supralevator. 
After incision and drainage of an anal abscess, an anal fistula remains in about half 
of the patients.14
Although many anal fistulas are considered simple and are easy to treat, others 
can be complex and treatment is challenging with a substantial risk of recurrence. It 
is not clear which factors contribute to the persistence of anal fistulas after surgery. 
The microbiology of anal abscesses has been well described.15-17 The bacteria cultured 
from perianal abscesses include bowel-derived organisms, skin-derived-organisms, 
or a combination of both. According to some authors, bowel-derived organisms are 
associated with subsequent occurrence of an anal fistula.15,16 However, this finding 
could not be confirmed by others.18 Only a few studies have been conducted to assess 
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the microbiology of cryptoglandular anal fistulas.19-21 These studies showed that the 
microbiota in anal fistulas is similar to the microbiota of anal abscesses. However, 
cultures yielded much smaller numbers of organisms in comparison with pus obtained 
from anal abscesses. Furthermore, they were not able to detect pathogenic organisms.
clAssificAtioN
The general accepted classification of anal fistulas is based on the course of the fistula 
tract in relation of the anal sphincter muscles.22 This classification is essential for the 
choice of treatment. Four main types of fistulas have been identified: intersphincteric, 
transsphincteric, suprasphincteric and extrasphincteric (Figure 1). Additionally, a dis-
tinction is made between high and low transsphincteric fistulas.
1.  Intersphincteric fistulas extend downward in the intersphincteric space to the 
perianal skin.
2.1.  Low transsphincteric fistulas pass through the lower third of the external anal 
sphincter before extending downward to the perianal skin.
2.2.  High transsphincteric fistulas pass through the upper or middle third of the 
external anal sphincter before extending downward to the perianal skin.
van Onkelen et al.
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Figure 1. Location of the four main anal fistula types
The fistula tracts are colored black. IS = Intersphincteric fistula; TS = Transsphincteric fistula; SS = Supra-
sphincteric fistula; ES = Extrasphincteric fistula; R = Rectum; PRM = Puborectal muscle; EAS = External 
anal sphincter; IAS = Internal anal sphincter; LA = Levator ani muscle.
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3.  Suprasphincteric fistulas extend in the intersphincteric space to a point above 
the puborectal muscle and transfer through the pelvic floor before extending 
downward through the ischiorectal space to the perianal skin.
4.  Extrasphincteric fistulas pass through the external anal sphincter and branch 
out into two tracts, one tract extends upward before passing through the 
pelvic floor and ending in the rectum and the other tract extends downward 
to the perianal skin.
surGicAl treAtmeNts
Hippocrates was probably the first to describe several treatments for anal fistulas 
and some of his techniques, such as a seton, are still used today.23 Many anal fistulas 
are considered simple and are easy to treat. However, treatment of more complex 
anal fistulas is challenging. The main objective in treatment is fistula healing with 
minimal fecal continence disturbances. Intersphincteric fistulas and low transsphinc-
teric fistulas are considered simple anal fistulas and require division of only a small 
portion of the anal sphincter muscle(s) by fistulotomy (lay-open) or fistulectomy 
(excision). In general, these surgical procedures lead only to minimal fecal continence 
disturbances. Complex anal fistulas require division of more anal sphincter muscle and 
therefore lead to more fecal continence disturbances if fistulotomy of fistulectomy 
are performed. Hence, alternative sphincter saving treatments are developed, such as 
transanal advancement flap repair (TAFR) and ligation of the intersphincteric fistula 
tract (LIFT). The choice of treatment will depend on the classification, location of the 
internal fistula opening and presence of associated abscesses.
fistulotomy
The classical treatment of anal fistulas is to surgically lay-open the fistula (fistulotomy). 
Although fistulotomy seems to be the most effective treatment for anal fistulas, a 
major drawback of this procedure is the need for anal sphincter division with the risk 
of subsequent fecal continence disturbances. Therefore, fistulotomy is only accepted 
for anal fistulas that require division of a small proportion of the anal sphincters, 
such as intersphincteric and low transsphincteric anal fistulas. For low transsphincteric 
fistulas it can be debated if fistulotomy is appropriate. Although the exact incidence of 
diminished fecal continence after fistulotomy for low transsphincteric fistulas cannot 
be assessed, data obtained from studies conducted so far suggest that fecal conti-
nence disturbances after surgical treatment of low fistulas are more common than 
previously thought (Table 1).
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transanal advancement flap repair
Fistulotomy is not appropriate for anal fistula types that require division of a large 
proportion of the anal sphincters, such as high transsphincteric anal fistulas. For these 
types of anal fistula a sphincter preserving treatment is more appropriate.
In 1902, Noble was the first to describe a sphincter preserving technique for rec-
tovaginal fistulas, transanal advancement flap repair (TAFR).24 Ten years later Elting 
applied this technique in patients with anal fistulas.25 The purpose of the flap is to 
severe communication between the anal canal and fistula tract after the diseased 
internal opening is removed. In 1948, Laird described a modification by adding fi-
bres of the internal anal sphincter muscle to the flap and this type of flap repair 
is currently considered by many surgeons to be the golden standard for sphincter 
preserving treatment of anal fistulas.26 The healing rate after TAFR varies between 60 
and 70%.27-31 Although anal sphincters are not divided, the rates of fecal continence 
disturbances after TAFR are up to 35%.31 While creating the flap, fibres of the internal 
anal sphincter are used to provide strength for the flap. Theoretically, this can affect 
fecal continence.
TAFR is performed with the patient in prone jack-knife position and the internal 
opening of the fistula exposed using a retractor. The internal opening is enlarged and 
the remaining crypt-bearing tissue is excised. A small rim of the anodermis, below the 
internal opening, is excised to create a neodentate line. The defect in the internal anal 
sphincter is closed. A flap consisting of mucosa, submucosa and some of the most 
superficial fibres of the internal anal sphincter, is raised from the level of the dentate 
line and mobilized over a distance of four to six centimetres proximally. The flap is 
advanced and sutured to the neodentate line. Subsequently, the external opening is 
Table 1. Impairment of fecal continence after fistulotomy for low anal fistula
Postoperative incontinence*
Author Year N Minor (%) Major (%) Minor and/or 
Major (%)
Garcia-Aguilar et al.42 1996 177 - - 39
Mylonakis et al.43 2001 65 9 0
Westerterp et al.44 2003 18 44 0
Chang and Lin.45 2003 45 - - 38
van der Hagen et al.46 2006 62 5 0
Toyonaga et al.47 2007 148 - - 20
Van Koperen et al.48 2008 63 41 5 -
Bokhari and Lindsey.49 2010 53 11 5 -
Atkin et al.50 2011 51 23 2 -
*Minor incontinence is incontinence for gas and/or soiling. Major incontinence is incontinence for solid 
and/or liquid stool.
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enlarged and the fistula tract is excised as far as possible until the outer border of the 
external anal sphincter (Figure 2).
ligation of the intersphincteric fistula tract
In 2009, ligation of the intersphincteric fistula tract (LIFT) has been introduced as a 
promising sphincter preserving alternative for TAFR.32 The LIFT technique is based on 
an original concept regarding eradication of the fistulous disease at its intersphincteric 
origin whilst preserving both anal sphincters. Rojanasakul was the first to describe 
this new technique. He observed primary fistula healing in 94% of his patients.32 
Other reports from Asia also revealed high healing rates, exceeding those obtained 
with the current sphincter preserving techniques.33,34 However, recent reports from 
the USA and Australia showed healing rates comparable with those after TAFR.35-37 
No fecal continence disturbances are describes after LIFT. Over the last few years, this 
new technique has generated considerable interest and LIFT is now perhaps as often 
applied as TAFR.
LIFT is performed with the patient in prone jack-knife position and the internal open-
ing of the fistula exposed using a retractor. Then a probe is introduced into the fistula 
tract. A curvilinear incision is made, just outside the intersphincteric groove. Dissection 
is continued in the intersphincteric space until the fistula tract is encountered. After 
isolation of the fistula tract the probe is removed and the tract is ligated with sutures 
close to the internal and external anal sphincter. Then the tract is transected between 
the two ligation points. Some surgeons do not transect but only ligate the fistula tract. 
Finally, the wound is loosely closed with sutures. Subsequently, the external opening is 
Figure 2. Steps involved in transanal advancement flap repair
A flap consisting of mucosa, sub mucosa and some of the most superficial fibres of the internal anal 
sphincter, is raised from the level of the dentate line and mobilized over the internal fistula opening 
(black dot). The flap is advanced and sutured to the neodentate line with absorbable sutures (red). 
R = Rectum; PRM = Puborectal muscle; EAS = External anal sphincter; IAS = Internal anal sphincter.
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enlarged and the fistula tract is excised as far as possible until the outer border of the 
external anal sphincter (Figure 3).
outliNe thesis
The general objective of the studies described in this thesis is to evaluate treatments 
for anal fistulas and to gain a better understanding of the pathogenesis of anal fistulas.
Chapter 2 presents an observational study on the different characteristics of high 
and low transsphincteric anal fistulas. Transsphincteric fistulas are classified as high 
or low. High transsphincteric fistulas pass through the upper or middle third of the 
external anal sphincter, whereas low transsphincteric fistulas traverse the lower third 
of the external anal sphincter. This classification has been used for selecting the 
optimal treatment and for supporting the choice between non-sphincter preserving 
and sphincter preserving techniques. Although the distinction between high and low 
transsphincteric anal fistulas is commonly practiced, it is unknown whether these 
fistulas have similar characteristics.
Figure 3. Steps involved in ligation of the intersphincteric fistula tract
Just outside the intersphincteric groove a curvilinear incision is made. Dissection is continued in the 
intersphincteric space until the fistula tract (black line) is encountered (large arrow). After isolation of 
the fistula tract in the intersphincteric space, the tract is ligated with absorbable sutures and transected 
between the two ligation points (small arrow). R = Rectum; PRM = Puborectal muscle; EAS = External 
anal sphincter; IAS = Internal anal sphincter; IS = Intersphincteric space.
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Chapter 3 describes a retrospective study on predictors of outcome after transanal 
advancement flap repair for high transsphincteric fistulas. It has been reported that 
smoking, obesity and previous attempts at repair adversely affect the outcome of 
transanal advancement flap repair.29,31,38,39 Because these findings could not be con-
firmed by other studies, it is still unclear whether these and other factors have an 
impact on the outcome.
Chapter 4 presents a prospective study on the effect of an additional ligation of 
the fistula tract on the outcome of transanal advancement flap repair for high trans-
sphincteric anal fistulas. Transanal advancement flap repair is successful in two of 
every three patients with a high transsphincteric anal fistula.27-31 It has been suggested 
that ongoing disease in the remaining fistula tract contributes to failure.
Chapter 5 addresses a prospective study on ligation of the intersphincteric fistula 
tract for low transsphincteric anal fistulas. Ligation of the intersphincteric fistula tract 
is a promising sphincter preserving technique.32-34 To date fistulotomy is still the treat-
ment of choice for low transsphincteric anal fistulas. However, studies suggest that 
fecal continence disturbances are more common than thought after fistulotomy.
Chapter 6 describes a retrospective study on transanal advancement flap repair 
combined with drainage of associated abscesses for high intersphincteric fistulas. 
Intersphincteric fistulas with a high upward extension, up to or above the level of the 
puborectal muscle, in the intersphincteric plane are rare and difficult to treat.
Chapter 7 presents a study on the prevalence of epithelialization of the fistula 
tract and the effect of epithelialization on the outcome of fistula surgery. It has been 
suggested that epithelialization of the fistula tract contributes to the failure of treat-
ment.40,41
Chapter 8 describes a study on the microbiota of anal fistulas by means of con-
ventional microbiological culture and 16S rRNA gene sequencing and immunohisto-
chemistry. Transanal advancement flap repair has been advocated as the treatment of 
choice for high transsphincteric anal fistulas, but fails in one of every three patients.27-31 
Persistence of anal fistulas might be the result of ongoing disease in the remaining 
fistula tract.
Chapter 9 addresses a study on cytokines in anal fistulas by means of advanced 
immuno-enzyme staining methods. Sphincter preserving procedures for the treatment 
of transsphincteric fistulas fail in one out of every three patients.27-31 It has been sug-
gested that failure is due to ongoing disease in the remaining fistula tract. Cytokines 
play an important role in inflammation. At present biologicals targeting cytokines are 
available. Therefore, detection and identification of cytokines in anal fistulas can have 
implications for future treatment modalities.
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Different characteristics of 
high and low transsphincteric 
fistulae
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AbstrAct
background
Transsphincteric fistulas are classified as high or low. Aim of this observational study 
was to determine whether high and low transsphincteric fistulas have different char-
acteristics or not.
method
A consecutive series of 300 patients with a transsphincteric fistula of cryptoglandular 
origin were studied. Two hundred patients with a high transsphincteric fistula under-
went transanal advancement flap repair and 100 patients with a low transsphincteric 
fistula underwent fistulotomy or ligation of the intersphincteric fistula tract at the Divi-
sion of Colon and Rectal Surgery, Erasmus MC, Rotterdam. Various patient and fistula 
characteristics were assessed. Data were analysed by means of logistic regression.
results
Low transsphincteric fistulas occurred more frequently in females (43% vs. 30% in 
high transsphincteric fistulas; P<0.05). The internal opening of these fistulas was 
predominantly located anteriorly (76% vs. 18% in high transsphincteric fistulas ; 
P<0.001). Mean age at surgery was lower in patients with a low transsphincteric 
fistula (42 vs. 47 years; P<0.001). In almost none of these patients an associated 
abscess was observed (4% vs. 54% in high transsphincteric fistulas; P<0.001). In 
multivariate analysis, the differences between high and low transsphincteric fistulas 
regarding location of their internal opening and the presence of associated abscesses 
remained significant (P<0.001).
conclusion
Although not significant in multivariate analysis, low transsphincteric fistulas occur 
more frequently at younger age and more often in female patients. Furthermore, 
these fistulas are predominantly located anteriorly and are rarely associated with an 
abscess. This was significant in univariate and multivariate analysis.
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iNtroductioN
Classification of anal fistulas is based on the course of the fistula tract in relation to 
the anal sphincters. Four main types of fistulas have been identified: intersphincteric, 
transsphincteric, suprasphincteric and extrasphincteric.1,2 Transsphincteric fistulas 
are classified as high or low. High transsphincteric fistulas pass through the upper 
or middle third of the external anal sphincter, whereas low transsphincteric fistulas 
traverse the lower third of the external anal sphincter. This classification has been 
used for selecting the optimal treatment and for supporting the choice between 
non-sphincter preserving procedures, such as fistulotomy, and sphincter preserving 
techniques, such as transanal advancement flap repair and ligation of the intersphinc-
teric fistula tract.3-6 Although the distinction between high and low transsphincteric 
fistulas has been widely accepted, it is unknown whether these fistulas have different 
characteristics or not. The aim of this observational study was to assess any differences 
in patient and fistula characteristics between high and low transsphincteric fistulas.
method
A consecutive series of 300 patients with a transsphincteric fistula of cryptoglandular 
origin were studied. This series consisted of the last 200 patients with a high trans-
sphincteric fistula who underwent transanal advancement flap repair (TAFR) and the 
last 100 patients with a low transsphincteric fistula who underwent fistulotomy or 
ligation of the intersphincteric fistula tract, in the time period preceding May 2013. 
For all patients this was their first surgical intervention at the Division of Colon and 
Rectal Surgery, Erasmus MC, Rotterdam. Prior to the procedure all patients underwent 
endoanal magnetic resonance imaging (EA MRI) to visualize the course of the fistula 
tract and to determine the presence and location of associated abscesses. Patients 
with a rectovaginal fistula or a fistula due to Crohn’s disease were excluded from 
this study. All patients provided informed consent meeting the standards set by the 
hospital’s Institutional Review Board.
Assessment of characteristics
The following characteristics of high and low transsphincteric fistulas were assessed: 
age, sex, presence of associated abscesses, location of internal fistula opening, body 
mass index, smoking, alcohol consumption, diabetes mellitus and hypertension. Pres-
ence of associated abscesses and location of the internal opening was assessed by 
EA MRI and careful examination during the procedure. Location of the internal fistula 
opening was described as anterior or posterior. Body mass index was calculated by 
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dividing the patient’s body mass (kilograms) by the square of their height (meters). 
In accordance to the World Health Organisation overweight was defined as a body 
mass index between 25 and 30 and obesity was defined as a body mass index of 
30 or more. Smoking was classified as excessive if the patient smoked 10 or more 
cigarettes a day. Diabetes mellitus and hypertension were included as characteristics if 
the patient used blood glucose-lowering medication or antihypertensive drugs respec-
tively. These aspects and other details regarding lifestyle such as smoking and alcohol 
consumption were obtained from the preoperative checklists. Further information was 
obtained from medical records by one author who had not participated in the surgical 
procedure.
statistical analysis
Continuous data are presented as mean values with standard deviation. Categorical 
data are presented as frequencies or percentages. Continuous data were tested with 
the Mann-Whitney U test and categorical data were tested with the Fisher’s exact 
test. Multivariate logistic regression was performed to adjust for all variables in the 
model. Bonferroni correction was used to adjust the P-values for multiple testing. 
The results from multivariate logistic regression were presented with and without 
Bonferroni correction. The sample size satisfies the rule of thumb of 10 cases per 
variable, which suggests that the sample size is adequate. Based on our extensive 
clinical experience in treatment of anal fistulas we expected significant differences 
in characteristics between patients with a high transsphincteric fistula and patients 
with a low transsphincteric fistula. The P-value threshold used for significance was 
0.05 and all tests were two-sided. Data were analysed by use of SPSS-IBM® software 
version 20.0 for Windows® (SPSS, Chicago, IL).
results
Twelve patient and fistula characteristics were assessed. Many, such as body mass 
index, overweight, obesity, smoking, excessive smoking, alcohol consumption, dia-
betes mellitus and hypertension, did not differ significantly between high and low 
transsphincteric fistulas. In univariate analysis, a significant difference between high 
and low transsphincteric fistulas was observed for mean age at surgery, gender, loca-
tion of the internal fistula opening and presence of associated abscesses. In patients 
with a high transsphincteric fistula, mean age at surgery was higher than in patients 
with a low transsphincteric fistula (47 vs. 42 years; P<0.001). Compared to high trans-
sphincteric fistulas, low transsphincteric fistulas occurred more frequently in female 
patients (43.0% vs. 29.5%; P=0.028). The male to female ratio was 1.3 for low 
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Table 1. Univariate analysis of patient and fistula characteristics of high and low transsphincteric fistulas 
(n = 300)
Characteristic
High transsphincteric 
fistulas (n = 200)
Low transsphincteric 
fistulas (n = 100) P-value*
Age (years) 47 ± 10.3 42 ± 11.8 <0.001**
Sex
Male 141 (70.5) 57 (57.0)
0.028
Female 59 (29.5) 43 (43.0)
Associated abscesses 108 (54.0) 4 (4.0) <0.001
Location of the internal opening
Anterior 35 (17.5) 76 (76.0)
<0.001
Posterior 165 (82.5) 24 (24.0)
BMI (kg/m2) 27.1 ± 4.3 26.8 ± 4.2 0.452**
Overweight, BMI 25-30 137 (68.5) 60 (60.0) 0.347
Obesity, BMI ≥ 30 49 (24.5) 21 (21.0) 0.622
Smoking 77 (38.5) 33 (33.0) 0.440
Excessive smoking 61 (30.5) 24 (24.0) 0.335
Alcohol consumption 117 (58.5) 51 (51.0) 0.307
Diabetes mellitus 8 (4.0) 4 (4.0) 1.000
Hypertension 23 (11.5) 12 (12.0) 1.000
Categorical variables are presented as numbers (%). Continuous values are expressed as mean ± SD. The 
baseline category for each variable is the presence of the characteristic, or stated otherwise in the table. 
BMI, body mass index. *Fisher’s exact test unless indicated otherwise; **Mann-Whitney U test.
Table 2. Multivariate analysis of patient and fistula characteristics of high and low transsphincteric 
fistulas (n = 300)
Characteristic OR
95% Confidence 
interval P-value*
Age (years) 1.0 0.96 - 1.02 0.529
Sex (male) 1.1 0.53 - 2.22 0.835
Associated abscesses 0.1 0.03 -0.27 <0.001**
Location of the internal 
opening (anterior)
8.5 4.17 - 17.48 <0.001**
BMI (kg/m2) 0.9 0.84 - 1.00 0.037
Smoking 1.1 0.55 - 2.37 0.716
Alcohol consumption 0.8 0.37 - 1.64 0.509
Diabetes mellitus 0.4 0.05 - 2.81 0.348
Hypertension 1.5 0.48 - 4.52 0.502
Categorical variables are presented as numbers (%). Continuous values are expressed as mean ± SD. The 
baseline category for each variable is the presence of the characteristic, unless indicated otherwise. BMI, 
body mass index. OR, odds ratio. *Logistic regression, adjustment for all variables in the model. P-values 
are presented without Bonferroni correction. **P-values that are significant after Bonferroni correction.
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transsphincteric fistulas and 2.4 for high transsphincteric fistulas. The internal fistula 
opening of low and high transsphincteric fistulas was located anteriorly in 76.0% and 
17.5% respectively (P<0.001). An associated abscess was observed in 4% and 54% 
respectively (P<0.001). The results of univariate analysis are presented in Table 1. After 
adjustment for all variables in the logistic regression model, the differences between 
high and low transsphincteric fistulas regarding location of their internal opening and 
the presence of associated abscesses remained significant (P<0.001). Both variables 
remained significant after application of the Bonferroni correction. The results of 
multivariate analysis are presented in Table 2. In patients with a high transsphincteric 
fistula, mean age at surgery was higher in men than in women (49.3 ± 9.6 vs. 42.6 ± 
10.4 years). In patients with a low transsphincteric fistula, a similar difference in mean 
age at surgery was observed between men and women (44.3 ± 11.3 vs. 39.8 ± 12.1 
years).
discussioN
The most common classification of anal fistulas is based on the course of the fistula 
tract in relation to the anal sphincters.1 Although Steltzner was the first to make 
a distinction between different types of fistulas,2 it was the classification according 
to Parks et al., which gained widely acceptance.1 Of the four main types of fistulas 
described by Parks et al., the transsphincteric fistula is the second most common 
type.1 Usually, a distinction is made between high and low transsphincteric fistulas. 
High transsphincteric fistulas pass through the upper or middle third of the external 
anal sphincter, whereas low transsphincteric fistulas traverse the lower third of the 
external anal sphincter. For many surgeons this classification is useful, because they 
consider patients with a low transsphincteric fistula eligible for fistulotomy. This 
procedure is not appropriate for patients with a high transsphincteric fistula. For 
these patients sphincter preserving techniques, such as transanal advancement flap 
repair and ligation of the intersphincteric fistula tract are preferable.3-6 Although the 
distinction between high and low transsphincteric fistulas is commonly practiced, it 
is unknown whether these fistulas have similar characteristics or not. To the authors 
knowledge, no reports are available regarding this aspect.
The present study demonstrated that high transsphincteric fistulas have a male pre-
dominance. This is in line with reports in the literature ranging from 2:1 to 5:1.7-10 Low 
transsphincteric fistulas were found to occur more frequently in females, resulting in 
a male-to-female ratio of 1:1. Most anal fistulas occur between the third and fifth 
decades of life.7,8 The mean age at surgery in high and low transsphincteric fistulas 
was 47 and 42 years, indicating that the latter occur more often at a younger age. 
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Although the differences regarding gender and age were found to be significant in 
univariate analysis, both variables were no longer significantly different in multivari-
ate analysis. This is probably due to the younger age of our female patients in both 
groups. In patients with a high transsphincteric fistula, the mean age at surgery was 
higher in men than in women (49 vs. 43 years). In patients with a low transsphincteric 
fistula, a similar difference in mean age at surgery was observed between men and 
women (44 vs. 40 years). Transsphincteric fistulas are often associated with one or 
more abscesses. Marks and Ritchie reported associated abscesses in 28% of all trans-
sphincteric fistulas.8 In a previous study, examining the complexity of high transsphinc-
teric fistulas, we observed associated abscesses in 36% of the patients. Abscesses 
occurred more frequently in patients with an internal opening located posteriorly than 
anteriorly (47% vs. 5%).11 In the present study, the incidence of associated abscesses 
was 54% in patients with a high transsphincteric fistula and 4% in those with a low 
transsphincteric fistula. Since our institution is a tertiary referral centre, we tend to 
see complex fistulas, which may partially explain the high incidence of associated 
abscesses in our patients with a high transsphincteric fistula. The different incidence 
of associated abscesses between high and low transsphincteric fistulas remained sig-
nificant after adjustment for all variables in the logistic regression model. The internal 
opening of low and high transsphincteric fistulas was found to be located anteriorly in 
76% and 18%. This difference remained statistical significant in multivariate analysis. 
Our findings suggest a correlation between the location of the internal opening and 
the presence of concomitant abscesses. Low transsphincteric fistulas have a predilec-
tion for the anterior side of the anal canal and are rarely associated with abscesses. 
High transsphincteric fistulas are almost exclusively located posteriorly and are ac-
companied by one or more abscesses in more than half of the patients.
The observation that low transsphincteric fistulas occur more frequently in females 
is difficult to explain. Such fistulas are predominantly located anteriorly. A possible 
explanation might be that females have more anal glands at the anterior side of the 
anal canal than men, but in a landmark study by Ian McColl no gender difference 
was observed in the distribution of anal glands.12 Based on current data, it seems 
unlikely that gender-specific distribution of anal glands can explain our finding that 
low transsphincteric fistulas occur more often in women.
The results of our observational study may have implications for clinical practice. In 
patients with a low transsphincteric fistula, fistulotomy is still advocated as the treat-
ment of choice because it is considered a simple, effective and safe procedure with a 
minimal risk of incontinence. The data suggest, however, that fecal continence is at 
risk following division of the lower third of the external anal sphincter, especially in 
females with an anterior fistula.13,14 Female patients are probably at risk because they 
have a shorter external anal sphincter, which is prone to damage during childbirth.15,16 
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In the present study almost half the patients with a low transsphincteric fistula were 
female. In these patients sphincter preserving techniques such as ligation of the inter-
sphincteric fistula tract may be preferable to conventional fistulotomy.
There are two limitations of this study. First this study is retrospective and second 
there is a potential selection bias, because our institution is a tertiary referral center 
for transsphincteric fistulas. The strengths of the study include the large number of 
patients, the large number of variables studied and the homogeneity of both patient 
groups.
In summary the study shows that high and low transsphincteric fistulas have different 
characteristics. Although not significant in multivariate analysis, low transsphincteric 
fistulas occurred more frequently at a younger age and more often in females. These 
fistulas were predominantly anterior and were rarely associated with an abscess.
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AbstrAct
background
Transanal advancement flap repair fails in one of every three patients with a high trans-
sphincteric fistula. It has been reported that smoking, obesity and previous attempts 
at repair adversely affect the outcome of transanal advancement flap repair. Because 
these findings could not be confirmed by other studies, it is still unclear whether 
these and other factors have an impact on the outcome. The aim of this study was to 
identify predictors of outcome in a large cohort of patients who underwent transanal 
advancement flap repair for a high transsphincteric fistula.
method
A consecutive series of 252 patients with a high transsphincteric fistula of crypto-
glandular origin were included. Patients with a rectovaginal or Crohn fistula were 
excluded. All patients underwent transanal advancement flap repair. Preoperatively, 
patients underwent endoanal magnetic resonance imaging. Seventeen patient and 
fistula related variables were assessed. The study was performed as a retrospective 
review.
results
Median duration of follow-up was 21 (range, 6-136) months. Failure rate at 3 years 
was 41% (95% CI 34.0-48.0). None of the studied variables predicted the outcome 
of flap repair except horseshoe extension. In univariate and multivariate analysis, 
significantly less failures were observed in patients with horseshoe extension (P<0.05).
conclusion
Of all studied variables horseshoe extension was found to be the only positive predic-
tor of outcome after flap repair for high transsphincteric fistulas.
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iNtroductioN
Fistulotomy is the only fistula treatment that actually works most of the time.1,2 A 
major drawback of this procedure is the need for sphincter division with the risk 
of subsequent fecal continence disturbances.2-4 Therefore, fistulotomy is inappropri-
ate for patients with a high transsphincteric fistula, passing through the upper or 
middle third of the external anal sphincter. The main objective in the treatment of high 
transsphincteric fistulas is healing without impairment of fecal continence. Therefore, 
sphincter preserving procedures have been developed for the treatment of high trans-
sphincteric fistulas, such as transanal advancement flap repair (TAFR) and ligation of 
the intersphincteric fistula tract (LIFT).5-7 Initially, reported healing rates after TAFR 
varied between 84% and 100%.8-11 However, it has become clear that TAFR fails in 
one of every three patients.12-18 It has been reported that smoking, obesity and previ-
ous attempts at repair adversely affect the outcome of TAFR.13,17,19,20 Because these 
findings could not be confirmed by other studies, it is still unclear whether these and 
other factors have an impact on the outcome of TAFR.17,18,20-22 The aim of this study 
was to identify predictors of outcome in a large cohort of patients who underwent 
TAFR.
method
study design
Between 2000 and 2012, a consecutive series of 252 patients with a high transsphinc-
teric fistula of cryptoglandular origin, underwent a TAFR as their first intervention at 
the Division of Colon and Rectal Surgery, Erasmus MC. In our institution, this was the 
treatment of choice for all patients with a high transsphincteric fistula. Before the 
procedure, patients underwent endoanal MRI to depict the course of the fistula tract 
and to determine the presence and location of associated abscesses. Patients with 
a rectovaginal fistula or a fistula attributed to Crohn’s disease were excluded from 
this study. Patients who underwent TAFR with additional procedures were excluded. 
All patients provided informed consent meeting the standards set by the hospital’s 
Institutional Review Board. All operations were performed by one surgeon (W.R.S.) 
and several colorectal surgery fellows.
operative technique
Patients underwent complete mechanical bowel preparation (polyethylene glycol: 
Klean-prep® Helsinn Birex Pharmaceuticals, Dublin, Ireland). After induction of 
general endotracheal anaesthesia, metronidazole (500 mg) together with cefuroxime 
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(1500 mg) was administered intravenously. The patient was placed in prone jack-knife 
position with the buttocks taped apart. Initially a Parks’ retractor (Park’s Anal Retrac-
tor, Slidell, LA) was used to expose the internal opening of the fistula. Since 2003, 
Lone Star Retractor was used for this purpose (Lone Star Retractor System, Lone Star 
Medical Products®, Inc. Houston, TX). The internal opening was enlarged and the 
remaining crypt-bearing tissue was excised. A small rim of the anodermis, below the 
internal opening, was excised to create a neodentate line. The defect in the internal 
anal sphincter was closed with absorbable sutures (2-0 Vicryl, Ethicon, Inc., Somer-
ville, NJ). A flap consisting of mucosa, submucosa and some of the most superficial 
fibers of the internal anal sphincter, was raised from the level of the dentate line and 
mobilized over a distance of 4 to 6 centimeters proximally. The flap was advanced and 
sutured to the neodentate line with absorbable sutures (2-0 Monocryl, Ethicon, Inc., 
Somerville, NJ).
Postoperative care
All patients were prescribed a stool softener for 2 weeks. There was no diet restriction. 
Patients were instructed to take a sitz bath 2 to 3 times daily until the wound was 
healed. After discharge patients were advised to restrict physical activity for 2 weeks.
follow-up
Patient visits were scheduled 2 weeks, 8 weeks and 6 months after surgery. Healing 
of the fistula was defined as complete wound healing and closure of all external 
openings in combination with absence of symptoms. Follow-up information regarding 
failure was obtained from medical charts or a follow-up telephone call by one author 
who had not participated in the surgical procedure.
Assessment of predictors
The following 17 patient and fistula related variables were assessed: age, sex, 
previous attempts at repair, TAFR before referral, presence of associated abscesses, 
preoperative seton drainage, location of the internal opening, horseshoe extension, 
postoperative drainage, overweight, obesity, smoking, alcohol consumption, diabetes 
and hypertension. Age was defined as <45 years or ≥45 years. Previous attempts 
at repair were defined as one or more surgical attempts at repair prior to referral. 
Drainage with a seton until the day of TAFR was defined as preoperative seton drain-
age. Location of the internal opening and horseshoe extension were assessed by EA 
MRI and careful examination during the procedure. Location of the internal fistula 
opening was described as anterior or posterior. Body mass index was calculated by 
dividing the patient’s body mass (kilograms) by the square of their height (meters). 
In accordance to the World Health Organisation overweight was defined as a body 
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mass index between 25 and 30, and obesity was defined as a body mass index of 
30 or more. Smoking was classified as excessive if the patient smoked 10 or more 
cigarettes a day. Diabetes mellitus and hypertension were included as potential predic-
tive factors if the patient used blood glucose-lowering medication or antihypertensive 
drugs respectively. These aspects and other details regarding lifestyle such as smoking 
and alcohol consumption were obtained from the preoperative checklists. Further 
information was obtained from medical charts or a follow-up telephone call by one 
author who had not participated in the surgical procedure.
statistical analysis
The risk of failure was calculated according to the Kaplan-Meier method. Comparisons 
between groups were done using the log-rank test. Data are presented as failure rates 
at 3 years after surgery. Multivariate analysis was performed by Cox regression of the 
significant variables. Variables used, were those with a P-value ≤ 0.05 according to 
univariate analysis, as well as age and sex. The P-value threshold used for significance 
was 0.05 and all tests were two-sided. Data were analyzed with SPSS IBM software 
version 20.0 for Windows (SPSS Inc, Chicago, IL).
results
The median duration of follow-up was 21 (range, 6-136) months. Failure rate at 3 
years after TAFR was 41% (95% CI 34.0-48.0) (Figure 1). Failure was not influenced 
by age and sex, nor by smoking and obesity. None of these or other patient related 
factors (presented in Table 1) was found to be an independent and significant predic-
tor of failure after TAFR. Fistula related factors, such as previous attempts at repair, 
TAFR before referral, preoperative seton drainage, presence of associated abscesses, 
location of the internal fistula opening, and postoperative drainage, did not affect the 
outcome of TAFR (Table 2). In contrast to our expectations, the failure rate in patients 
with horseshoe extension was significantly lower than in patients with a more simple 
fistula with a direct course (32% (95% CI 23.0-41.0) vs. 51% (95% CI 40.6-61.4); 
P=0.005). After adjustment for age and sex, this finding remained statistical significant 
(P=0.008; Table 3).
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Table 1. Patient related factors and failure rate of transanal advancement flap repair (n = 252)
n
Failure rate at 
3 years
95% 
Confidence 
interval
P-value
Age
< 45 years 103 (41) 47 35.6 - 58.4
0.164
≥ 45 years 149 (59) 36 27.4 - 44.6
Sex
Male 180 (71) 37 29.0 - 45.0
0.116
Female 72 (29) 50 36.9 - 63.1
Overweight, BMI 25-30
Yes 108 (57) 40 31.4 - 48.6
0.777
No 82 (43) 39 27.1 - 50.9
Obesity, BMI ≥ 30
Yes 57 (23) 35 21.3 - 48.7
0.943
No 190 (77) 40 32.0 - 48.0
Smoking
Yes 102 (42) 39 28.4 - 49.6
0.599
No 142 (58) 39 29.7 - 48.2
Excessive smoking
Yes 84 (35) 36 24.4 - 47.6
0.188
No 159 (65) 41 32.2 - 49.8
Figure 1. Kaplan-Meier curve of failure rate after transanal advancement flap repair
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Table 1. (continued)
n
Failure rate at 
3 years
95% 
Confidence 
interval
P-value
Alcohol consumption
Yes 147 (61) 35 26.2 - 43.8
0.083
No 96 (39) 46 34.6 - 57.4
Diabetes mellitus
Yes 9 (4) 37 3.5 - 70.5
0.690
No 223 (96) 41 33.6 - 48.4
Hypertension
Yes 26 (11) 39 18.8 - 59.2
0.733
No 206 (89) 42 34.2 - 49.8
Univariate analysis. Variables are presented as numbers (%). Failure rates are presented in percentages. 
BMI = body mass index.
Table 2. Fistula related factors and failure rate of transanal advancement flap repair (n = 252)
n
Failure rate 
at 3 years
95% 
Confidence 
interval P-value
Previous attempts at repair
0 104 (41) 39 27.8 - 50.2
0.400
≥ 1 148 (59) 42 33.2 - 50.8
Two or more previous attempts at repair
≤ 1 184 (73) 39 30.8 - 47.2
0.445
≥ 2 68 (27) 44 31.1 - 56.9
TAFR prior to referral
Yes 35 (14) 52 33.6 - 70.4
0.091
No 217 (86) 39 31.6 - 46.4
Preoperative seton drainage
Yes 38 (15) 27 11.1 - 42.9
0.104
No 214 (85) 43 35.4 - 50.6
Associated abscesses
Yes 116 (46) 42 32.0 - 52.0
0.342
No 136 (54) 39 29.4 - 48.6
Location of the internal opening
Anterior 50 (20) 36 21.1 - 50.9
0.549
Posterior 202 (80) 42 34.1 - 49.9
Horseshoe extension
Yes 117 (46) 32 23.0 - 41.0
0.005
No 135 (54) 51 40.6 - 61.4
Postoperative drainage
Yes 116 (46) 42 32.0 - 52.0
0.342
No 136 (54) 39 29.4 - 48.6
Univariate analysis. Variables are presented as numbers (%). Failure rates are presented in percentages. 
TAFR = transanal advancement flap repair.
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discussioN
In a consecutive series of 252 patients with a high transsphincteric fistula of cryp-
toglandular origin who underwent a TAFR at our institution, 17 potential predictors 
of outcome were assessed. Our study showed that TAFR is an attractive sphincter 
preserving treatment for high transsphincteric fistulas and that the outcome of TAFR 
was significantly better in patients with horseshoe extension.
Limitations of this study are the retrospective nature, a single surgeon series and a 
potential selection bias caused by the tertiary referral center status of our institution. 
Strengths of the study are the large number of patients, the large number of variables 
studied, the homogeneity of the patient group, and the long median duration of 
follow-up.
According to Garcia-Aguilar et al. various factors are associated with recurrence 
after fistula surgery, including complex type of fistula, horseshoe extension, lack of 
identification or lateral location of the internal fistulous opening, previous fistula 
surgery and the surgeon performing the procedure.4 These factors were analyzed in 
more than 600 patients who underwent fistula surgery. However, in only 3 out of 108 
patients with a transsphincteric fistula was a flap repair performed. Data obtained 
from this study did not elucidate the value of these factors as a predictor of outcome 
of flap repair.
Complex type of fistula and lack of identification of the internal fistulous opening 
has also been identified as predictors of outcome by Jordan et al..23 These authors 
examined a heterogeneous group of 279 patients who underwent a great variety of 
procedures. However, the small number of patients that underwent a flap repair (26 
out of 53 patients with a high transsphincteric fistula) was one of the limitations of 
Table 3. Cox regression of horse shoe extension adjusted for age and sex (n = 252)
n HR
95% HR 
Confidence 
interval P-value
Horseshoe extension
Yes 117 (46.4) 1 -
0.008
No 135 (53.6) 1.8 1.2 - 2.7
Age
< 45 years 103 (40.9) 1.2 0.8 - 1.9
0.433
≥ 45 years 149 (59.1) 1 -
Sex
Male 180 (71.4) 1 -
0.220
Female 72 (28.6) 1.3 0.8 - 2.1
Multivariate analysis. Variables are presented as numbers (%). HR = hazard ratio.
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this study. A previous study, conducted at our institution, revealed that the complexity 
of high transsphincteric fistulas, characterized by horseshoe extensions and the pres-
ence of associated abscesses, does not affect the outcome of flap repair. In contrast 
to our expectations, the healing rate of fistulas with a direct course was significantly 
lower than the healing rate of fistulas with horseshoe extension.24 This is consistent 
with the findings of the present study.
Special attention has also been given to the history of previous attempts at repair as 
potential predictor of outcome. It has been suggested that flap repair is less feasible 
in an area of scar tissue with reduced blood supply. Ellis and Clark performed a flap 
repair in 68 patients. They observed a significant higher recurrence rate in the patients 
with a history of previous attempts at repair. Their patient group, however, was not 
homogeneous and consisted of 39 women with a rectovaginal fistula and 29 patients 
with a transsphincteric fistula.19 The question is whether their conclusion is justified 
in view of the small number of patients with a transsphincteric fistula. An earlier 
study, conducted at our own institution, involved 44 patients and revealed that the 
outcome after flap repair was less favorable in patients who had undergone two 
or more previous attempts at repair.13 This earlier finding could not be confirmed 
by the present study, which was composed of a large, homogeneous group of 252 
patients. It seems likely that our earlier conclusion was premature because of the small 
number of patients. Three other studies also revealed that previous attempts at repair 
do not adversely affect the outcome after TAFR.18,21,22 Therefore, it seems unlikely that 
a history of previous attempts at repair is an independent predictor of outcome after 
TAFR. This proposition is supported by our observation that even previous flap repairs, 
performed before referral, did not affect the healing rate. This is in accordance with 
the finding that repeat flap repairs are worthwhile and successful in two of every three 
patients.25
Smoking is another aspect that received attention. A previous study, conducted 
at our institution revealed that excessive smoking (more than 10 cigarettes a day) 
adversely affects the outcome of TAFR.17 It was suggested that smoking may have a 
detrimental effect on rectal mucosal blood flow, thereby contributing to disruption of 
the flap. In an additional study, we observed that rectal mucosal blood flow before 
and shortly after TAFR was not significantly lower in patients who smoke than in those 
who do not. Furthermore, it was shown that rectal mucosal blood flow did not affect 
the outcome of TAFR.26 Therefore, there was still doubt as to the adverse effect of 
smoking on fistula healing after flap repair. Ellis and Clark are the only ones, who also 
observed a lower healing rate after flap repair among smokers.19 This adverse effect, 
however, could not be demonstrated by others.20,21 The present study shows that even 
excessive smoking is not an independent predictor of outcome for flap repair.
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Recently, Schwandner reported that obesity, defined as a body mass index (BMI) 
higher than 30, is a negative predictive factor for the outcome after flap repair.20 This 
finding is not in accordance with the data obtained from the present study, demon-
strating that healing is not affected by overweight (BMI 25-30) or obesity (BMI ≥ 30). 
Similar findings were reported by Zimmerman et al..17
This study shows that the outcome after TAFR for high transsphincteric fistulas 
is significantly better in patients with horseshoe extension. An explanation for this 
unexpected finding might be the possibility that the course of the fistula depends 
on the severity of the fistulous disease. The more fulminant the fistulous disease, the 
more perpendicular the fistula might traverse through the anal sphincters, resulting 
in a direct course to the external fistula opening. Further research is warranted to 
investigate this aspect.
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Is it possible to improve 
the outcome of transanal 
advancement flap repair for 
high transsphincteric fistulas 
by additional ligation of the 
intersphincteric fistula tract?
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AbstrAct
background
Transanal advancement flap repair is successful in two of every three patients with a 
cryptoglandular fistula passing through the middle or upper third of the external anal 
sphincter. It has been suggested that ongoing disease in the remaining fistula tract 
contributes to failure. Ligation of the intersphincteric fistula tract might be a useful 
tool to eradicate this ongoing disease. The aim of the present study was to evaluate 
the effect of an additional ligation of the fistula tract on the outcome of transanal 
advancement flap repair.
method
A consecutive series of 41 patients with a high transsphincteric fistula of cryptoglan-
dular origin were included. Ligation of the intersphincteric fistula tract was performed 
in addition to flap repair. Early and late complications were recorded. Continence 
scores were determined with the use of the Fecal Incontinence Severity Index.
results
Median duration of follow-up was 15 months. Primary healing was observed in 21 
patients (51%). Of the 20 patients with a failure, the original transsphincteric fistula 
persisted in 12 patients. In 8 patients, the transsphincteric fistula was converted into 
an intersphincteric fistula. These patients underwent subsequent fistulectomy, which 
was successful in all of them. The overall healing rate was 71%.
conclusion
Ligation of the intersphincteric fistula tract procedure is prone to infection and does 
not enhance the outcome of flap repair.
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iNtroductioN
Fistulotomy is the only fistula treatment that actually works most of the time.1,2 A 
major drawback of this procedure is the need for sphincter division with subsequent 
continence disturbances.3,4 Therefore, fistulotomy is not appropriate for patients 
with a transsphincteric fistula, passing through the upper or middle third of the 
external anal sphincter. The principal goal in the treatment of high transsphincteric 
fistulas is healing without impaired continence. In contrast to fistulotomy, transanal 
advancement flap repair (TAFR) provides a more useful tool to minimize sphincter 
damage.5-11 However, it has become clear that this procedure fails in 1 of every 3 
patients.3,5,8-10 Until now, no predictive factors for failure have been identified. In a 
previous study performed at our institution, the outcome of repeat flap repair was 
examined in 26 patients, who encountered a failure after the initial procedure.12 In all 
of these patients complete healing of the advancement flap was noticed, except at 
the site of the original internal opening. This remarkable clinical finding and the lack 
of predictive factors for failure have made the question of whether ongoing disease 
in the remaining tract contributes to persistence of the fistula after flap repair. Most 
of the remaining tract is located in the intersphincteric plane near the origin of the 
fistula. Recently, ligation of the intersphincteric fistula tract (LIFT) has been introduced 
as an attractive sphincter-preserving alternative.13-18 Based on the promising results 
of this new technique, it was questioned whether this procedure would be a useful 
candidate for the eradication of the ongoing disease in the remaining fistula tract, 
thereby improving the outcome of TAFR. The present study was conducted to assess 
the effect of an additional LIFT procedure on the outcome of TAFR and to evaluate the 
impact of both combined procedures on fecal continence.
method
Between June 2009 and December 2010, a consecutive series of 41 patients with a 
high transsphincteric fistula of cryptoglandular origin underwent a LIFT procedure 
in addition to their flap repair. Patients with a rectovaginal fistula or a fistula due to 
Crohn’s disease were excluded from this study. The present series comprised 32 men 
and 9 women. Median age at the time of treatment was 42 (range, 20-69) years. 
Twenty-one patients had undergone one or more previous attempts at repair before 
referral. All patients provided written informed consent meeting the standards set 
by the hospital’s institutional review board. All operations were performed by one 
surgeon (W.R.S.).
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operative technique
All patients received complete mechanical bowel preparation (polyethylene glycol: 
Klean-prep Helsinn Birex Pharmaceuticals, Dublin, Ireland). After induction of general 
endotracheal anesthesia, metronidazole (500 mg) together with cefuroxime (1500 mg) 
was administered intravenously. The patient was placed in a prone jackknife position 
with the buttocks taped apart. The internal opening of the fistula was exposed by the 
use of a Lone Star retractor (Lone Star Retractor System, Lone Star Medical Products, 
Inc. Houston, TX). Then, a probe was introduced into the fistula tract. A curvilinear 
incision was made, just outside the intersphincteric groove. Dissection was continued 
in the intersphincteric plane until the fistula tract was encountered. After isolation 
of the fistula tract, the probe was removed and the tract was ligated with synthetic 
absorbable polyglactin sutures (3/0 Vicryl, Ethicon, Inc., Somerville, NJ) close to the 
internal and external anal sphincter. The tract was then transected between the 2 
ligation points. Finally, the wound was loosely closed with interrupted, synthetic non-
absorbable nylon sutures (3/0 Ethilon, Ethicon, Norderstedt, Germany). Subsequently, 
the external opening was enlarged and the fistula tract was excised as far as possible 
until the outer border of the external anal sphincter. The crypt-bearing tissue around 
the internal opening as well as the overlying anodermis was then excised. The defect 
in the internal anal sphincter was closed with absorbable sutures. A flap consisting 
of mucosa, submucosa, and some of the most superficial fibers of the internal anal 
sphincter was raised from the level of the dentate line and mobilized over a distance 
of 4 to 6 cm proximally. The flap was advanced and sutured to the neodentate line 
with absorbable sutures.
Postoperative care
All patients were immobilized for 5 days. During these days, they received a clear 
liquid diet. During this period, metronidazole and cefuroxime were administered 
intravenously 3 times daily.
follow-up
Patient visits were scheduled 2 weeks, 3 months, and 6 months after surgery. Healing 
of the fistula was defined as complete wound healing and closure of all external open-
ings in combination with absence of symptoms. Additional follow-up information was 
obtained from both a questionnaire and telephone communication by one author 
who had not participated in the surgical procedure.
Assessment of fecal continence
Fecal continence was evaluated by use of the Rockwood Fecal Incontinence Severity 
Index (RFISI). This index was assessed before and 6 months after the procedure.
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statistical analysis
For statistical analysis the Fisher exact probability test was used. The limit of statistical 
significance was set at P=0.05.
results
The median duration of follow-up was 15 (range, 7-21) months. Primary fistula heal-
ing was observed in 21 patients (51%). Four of these patients (19%) encountered 
purulent discharge at the intersphincteric wound. This problem resolved sponta-
neously and did not adversely affect the final outcome. In all failures, we noticed 
complete healing of the flap, except at the site of the original internal opening. Of the 
20 patients with a failure, 12 had persistent discharge both at the original external 
opening and at the intersphincteric wound. In 8 patients, the external component was 
gone, and discharge occurred only at the intersphincteric wound. This conversion to 
a low intersphincteric fistula enabled simplified subsequent fistulectomy. This second 
procedure was successful in all 8 patients, eventually resulting in an overall healing 
rate of 71%. Of the 12 patients whose surgery failed without an intersphincteric 
pattern, 4 patients were successfully treated with a repeat TAFR. The other 8 patients 
were treated with long-term indwelling seton drainage. The median time to failure 
was within 3 months in all patients. The healing rate was not affected by age, sex 
of the patients, number of prior attempts, preoperative use of seton drainage for at 
least 2 months, or fistula characteristics (Table 1). Before the combined procedures, 
the median RFISI was 10 (range, 0-37). Six months after surgery, the median RFISI 
score was not changed significantly (RFISI = 7; range, 0-29). The RFISI was found to be 
improved in 6 patients and worsened in 1 patient. In 34 patients, RFISI did not change 
after the procedure.
Table 1. Comparison of baseline patient and fistula characteristics
Variable Success Failure P-value
Age, median (range) 43 (31-69) 37 (20-67) 0.10
Sex, % male 71 65 0.68
Prior attempts at repair (≥1), % 42 60 0.35
Preoperative seton drainage, % 38 50 0.45
Fistula duration, months 16 18 0.62
Internal opening, %
Posterior 76 75
Anterior 23 20
Lateral 1 5 0.64
Horseshoe extension, % 29 50 0.14
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The main objective in the treatment of transsphincteric fistulas is healing of the fistula 
without impairment of fecal continence. In patients with a low transsphincteric fistula, 
passing through the lower third of the external anal sphincter, this goal can be achieved 
by simple “lay open” fistulotomy.1,2 This procedure is not appropriate for patients 
with a high transsphincteric fistula, passing through the middle or upper third of the 
external anal sphincter. During the past decades, a sphincter-saving procedure such 
as flap repair, the use of glue and plugs, and recently the LIFT procedure have been 
introduced as alternative options for the treatment of high transsphincteric fistulas. 
Although TAFR provides a useful tool to obtain fistula healing without serious impair-
ment of fecal continence, this procedure fails in 1 of every 3 patients.5 Until now, no 
predictive factors for failure have been identified. In a previous study, conducted at 
our institution, the outcome of repeat flap repair was examined in 26 patients, who 
encountered a failure after the initial procedure.12 In all of these patients, complete 
healing of the advancement flap was noticed, except at the site of the original in-
ternal opening. This remarkable clinical finding and the lack of predictive factors for 
failure have raised the question of whether ongoing disease in the remaining tract 
contributes to persistence of the fistula after flap repair. Previous attempts, including 
the additional use of glue and plugs, failed to improve the outcome of TAFR.19-22 
Recently, the LIFT procedure has been introduced as a promising sphincter-preserving 
procedure. Rojanasakul14 was the first to describe this new technique. He observed 
primary healing of the fistula in 94% of his patients. Another report from Malaysia 
also revealed high healing rates, exceeding those obtained with the current sphincter 
saving techniques.17 However, recent reports from the United States showed more 
modest results, indicating that the LIFT procedure, like the flap repair, fails in 1 of every 
3 patients.13,18 The LIFT procedure is based on an original concept of eradication of 
the fistulous disease at its origin without sphincter damage. Following adequate flap 
repair, a short tract remains in the intersphincteric plane near the origin of the fistula. 
It has been suggested that ongoing inflammation in this remaining tract contributes 
to failure after flap repair. It was questioned whether the LIFT procedure enables the 
eradication of this ongoing inflammation, thereby improving the results of TAFR. The 
outcome of the present study, with a primary healing rate of only 51%, is rather 
disappointing and clearly demonstrates that LIFT provides no benefits. There was no 
flap loss. In all failures, we noticed complete healing of the flap, except at the site 
of the original internal opening. This remarkable finding does suggest that ongoing 
inflammation in the remaining fistula tract contributes to persistence of the fistula, 
but we were not able to resolve this with addition of the LIFT procedure. In patients 
treated with TAFR only, progress of residual sepsis is still possible toward the enlarged 
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external opening. In patients who are treated with LIFT only, the opposite route toward 
the anal canal is an escape for the ongoing inflammation. The poor healing rate might 
be caused by entrapment of residual sepsis between the ligation site and the flap. 
However, conversion of the transsphincteric fistula to a low intersphincteric fistula was 
the only positive side effect of the additional LIFT procedure. This conversion was ob-
served in 20% of the patients and enabled a subsequent and simplified fistulectomy. 
This phenomenon has also been reported after ligation of the intersphincteric fistula 
tract as a single procedure.13 Following both combined procedures, no deterioration 
of continence was observed. In the past it had been reported that TAFR is associated 
with disturbed continence. In a previous study, we were able to demonstrate that 
the use of a Parks retractor has a deteriorating effect on fecal continence.23 This side 
effect was not observed after flap repair with the use of a Lone Star retractor. In the 
present study, the same retractor was used to gain access to the anal canal. In our 
opinion, avoidance of anal stretch is the major contributing factor in the preserva-
tion of fecal continence. Our conservative postoperative management of inpatient 
stay, immobilization, clear liquid diet, and postoperative antibiotics is based on expert 
opinions. We did not change our policy during this study to be able to compare the 
results with our historical group. In the future, we will introduce an accelerated-stay 
program including single dose prophylactic antibiotics, paracetamol for analgesia, 
free oral fluid and food immediately after the operation supplemented by laxatives, 
and enforced mobilization. Such a regimen seems especially worthwhile after the 
LIFT procedure. Although randomized controlled trials comparing TAFR and LIFT are 
lacking, there is some evidence that the LIFT procedure, like the flap repair, also fails in 
1 of every 3 patients. Flap repair is rather demanding, whereas LIFT is simple and easy 
to perform. Furthermore, patients who are approached with the LIFT procedure can be 
treated as outpatients. Therefore, it is expected that the LIFT procedure will become 
the first choice for high transsphincteric fistulas. However, flap repair will remain 
important in case of a persistent fistula after 1 or 2 LIFT procedures and in patients 
with a fistula not amenable for LIFT, such as those with intersphincteric horseshoe 
extension or an associated intersphincteric abscess. Until now, all our attempts to 
improve the outcome of flap repair have failed. In our experience, it is not possible to 
increase the fistula closure rate after TAFR, either by additional use of glue or plugs, or 
by combining the flap repair with an additional LIFT procedure as demonstrated in the 
present study. Failure in 1 of every 3 patients seems to be inevitable.
52 Chapter 4
refereNces
 1. Van der Hagen SJ, Baeten CG, Soeters PB, et al. Long-term outcome following mucosal 
advancement flap for high perianal fistulas and fistulotomy for low perianal fistulas: recur-
rent perianal fistulas: failure of treatment or recurrent patient disease? Int J Colorectal Dis. 
2006;21:784-790.
 2. Whiteford MH, Kilkenny J III, Hyman N, et al. Practice parameters for the treatment of perianal 
abscess and fistula-in-ano (revised). Dis Colon Rectum. 2005;48:1337-1342.
 3. Lunniss PJ, Kamm MA, Phillips RK. Factors affecting continence after surgery for anal fistula. Br 
J Surg. 1994;81:1382-1385.
 4. Van Tets WF, Kuijpers HC. Continence disorders after anal fistulotomy. Dis Colon Rectum. 
1994;37:1194-1197.
 5. Mitalas LE, Gosselink MP, Oom DM, et al. Required length of follow-up after transanal ad-
vancement flap repair of high transsphincteric fistulas. Colorectal Dis. 2008;11:726-728.
 6. Aguilar PS, Plasencia G, Hardy TG Jr, et al. Mucosal advancement in the treatment of anal 
fistula. Dis Colon Rectum. 1985;28:496-498.
 7. Kodner IJ, Mazor A, Shemesh EI, et al. Endorectal advancement flap repair of rectovaginal and 
other complicated anorectal fistulas. Surgery. 1993;114:682-689.
 8. Zimmerman DD, Delemarre JB, Gosselink MP, et al. Smoking affects the outcome of transanal 
mucosal advancement flap repair of transsphincteric fistulas. Br J Surg. 2003;90:351-354.
 9. Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of 
failure? Dis Colon Rectum. 2002;45:1616-1621.
 10. Schouten WR, Zimmerman DD, Briel JW. Transanal advancement flap repair of transsphincteric 
fistulas. Dis Colon Rectum. 1999;42:1419-1422.
 11. Ortiz H, Marzo J. Endorectal flap advancement repair and fistulectomy for high transsphincteric 
and suprasphincteric fistulas. Br J Surg. 2000;87:1680-1683.
 12. Mitalas LE, Gosselink MP, Zimmerman DD, et al. Repeat transanal advancement flap repair: 
impact on the overall healing rate of high transsphincteric fistulas and on fecal continence. Dis 
Colon Rectum. 2007;50:1508-1511.
 13. Bleier H, Moloo H, Goldberg S. Ligation of the intersphincteric fistula tract (LIFT): an effective 
new technique for complex fistulae. Dis Colon Rectum. 2010;53:43-46.
 14. Rojanasakul A. LIFT procedure: a simplified technique for fistula-in-ano. Tech Coloproctol. 
2009;13:237-240.
 15. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, et al. Total anal sphincter saving technique 
for fistula-in-ano: the ligation of intersphincteric fistula tract. J Med Assoc Thai. 2007;90:581-
586.
 16. Lunniss PJ. LIFT procedure: a simplified technique for fistula-in-ano. Tech Coloproctol. 
2009;13:241-242.
 17. Shanwani A, Azmi M, Amri N. The ligation of intersphincteric fistula tract (LIFT) for fistula-in-
ano: sphincter saving technique. Dis Colon Rectum. 2010;53:39-42.
 18. Aboulian A, Kaji AH, Kumar RR. Early results of ligation of the intersphincteric fistula tract for 
fistula-in-ano. Dis Colon Rectum. 2011;54:289-292.
 19. Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, con-
trolled study. Dis Colon Rectum. 2006;49:1736-1740.
 20. Mitalas LE, Van Onkelen RS, Gosselink MP, et al. The anal fistula plug as an adjunct to transanal 
advancement flap repair. Dis Colon Rectum. 2010;53:1713.
Is it possible to improve the outcome of TAFR for high transsphincteric fistulas by additional LIFT? 53
4
 21. Van Koperen PJ, Wind J, Bemelman WA, et al. Fibrin glue and transanal rectal advancement 
flap for high transsphincteric perianal fistulas: is there any advantage? Int J Colorectal Dis. 
2008;23:697-701.
 22. Alexander SM, Mitalas LE, Gosselink MP, et al. Obliteration of the fistulous tract with Bio-
Glue adversely affects the outcome of transanal advancement flap repair. Tech Coloproctol. 
2008;12:225-258.
 23. Zimmerman DD, Gosselink MP, Hop WC, et al. Impact of two different types of anal retrac-
tor on fecal continence after fistula repair: a prospective, randomized clinical trial. Dis Colon 
Rectum. 2003;46:1674-1679.

12
3
4
5
6
7
8
9
10
11
12
chapter 5
Ligation of the intersphincteric 
fistula tract in low 
transsphincteric fistulae: A new 
technique to avoid fistulotomy
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AbstrAct
background
To date fistulotomy is still the treatment of choice for patients with a transsphincteric 
fistula passing through the lower third of the external anal sphincter, because it is a 
simple, effective and safe procedure with a minimal risk of incontinence. However, 
data suggest that the risk of impaired continence following division of the lower 
third of the external anal sphincter is not insignificant, especially in female patients 
with an anterior fistula and patients with diminished anal sphincter function. It has 
been shown that ligation of the intersphincteric fistula tract (LIFT) is a promising 
sphincter-preserving technique. Therefore, we questioned whether LIFT could replace 
fistulotomy in patients with a low transsphincteric fistula.
method
A consecutive series of 22 patients with a low transsphincteric fistula of cryptoglan-
dular origin underwent LIFT. Continence scores were determined using the Rockwood 
Fecal Incontinence Severity Index.
results
Median follow-up was 19.5 months. Primary healing was observed in 18 (82%) 
patients. In the four patients without primary healing, the transsphincteric fistula 
was converted into an intersphincteric fistula. These patients underwent subsequent 
fistulotomy with preservation of the external anal sphincter. The overall healing rate 
was 100%. Six months after surgery, the median incontinence score was not changed 
significantly.
conclusion
Low transsphincteric fistulae can be treated successfully by LIFT, without affecting 
faecal continence. Division of the lower part of the external anal sphincter is no lon-
ger necessary in the treatment of low transsphincteric fistulae, which is essential for 
patients with compromised anal sphincters.
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iNtroductioN
Fistulotomy is the only fistula treatment that actually works most of the time.1,2 A 
major drawback is the need for sphincter division with the risk of a faecal continence 
disturbance.3-5 Therefore, fistulotomy is not appropriate for patients with a high trans-
sphincteric fistula, passing through the upper or middle third of the external anal 
sphincter. Today, sphincter-preserving procedures are available for the treatment of 
these high transsphincteric fistulae, such as flap repair, the use of glue and plugs, 
and ligation of the intersphincteric fistula tract (LIFT). For patients with a low trans-
sphincteric fistula fistulotomy is still advocated as the treatment of choice because 
it is considered a simple, effective and safe procedure with a minimal risk of faecal 
incontinence. However, data suggest that the risk of diminished faecal continence 
following division of the lower third of the external anal sphincter is not insignificant, 
especially in female patients with an anterior fistula.3,4 Female patients are probably at 
risk because they have a shorter external anal sphincter anteriorly, which is prone to 
damage during childbirth.6,7 Recent findings indicate that for most patients it is more 
important to minimize their risk of diminished faecal continence than to have a highly 
successful treatment for their fistula.8 LIFT is a new sphincter-preserving technique 
for the treatment of transsphincteric fistulae. The reported healing rates after this 
procedure are promising.9-15 We therefore questioned whether fistulotomy, including 
division of the lower part of the external anal sphincter, may be replaced by LIFT in 
patients with a low transsphincteric fistula.
method
Between June 2009 and March 2012, a consecutive series of 22 patients with a low 
transsphincteric fistula of cryptoglandular origin underwent LIFT. Prior to the proce-
dure all patients underwent endoanal MRI to visualize the course of the fistula tract. 
Patients with a rectovaginal fistula or a fistula due to Crohn’s disease were excluded. 
The present series included 13 men and nine women. The median age at the time of 
treatment was 45 (17-59) years. Ten patients had undergone one or more previous 
attempts at repair before referral. All patients provided informed consent meeting 
the standards set by the hospital’s Institutional Review Board. All operations were 
performed by one surgeon (WRS).
operative technique
After induction of general endotracheal anaesthesia, metronidazole (500 mg) and 
cefuroxime (1500 mg) were administered intravenously. With the patient in the prone 
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jack-knife position the internal opening of the fistula was exposed using a lone-star 
retractor (Lone Star Retractor System; Lone Star Medical Products Inc., Houston, Texas, 
USA). A probe was then introduced into the fistula track and a curvilinear incision 
was made, just outside the intersphincteric groove. Dissection was continued in the 
intersphincteric plane until the fistula track was encountered. After its isolation the 
probe was removed and the track was ligated with absorbable sutures (3 ⁄ 0 Vicryl; 
Ethicon Inc., Somerville, New Jersey, USA) close to the internal and external anal 
sphincters. The track was then transected between the two ligation points. The wound 
was loosely closed with interrupted, non-absorbable sutures (3 ⁄ 0 Ethilon; Ethicon, 
Norderstedt, Germany). Subsequently, the external opening was enlarged and the 
fistula track was excised as far as possible until the outer border of the external anal 
sphincter. Postoperatively all patients were prescribed a stool softener for 2 weeks. 
There was no diet restriction. Patients were instructed to take a sitz bath two to three 
times daily until the wound was healed. After discharge patients were advised to 
restrict physical activity for 2 weeks.
follow-up
Patient visits were scheduled at 2, 8 and 26 weeks after surgery. Healing of the fistula 
was defined as complete wound healing and closure of all external openings in com-
bination with the absence of symptoms. Further follow-up information was obtained 
from both a questionnaire and telephone communication by one author who had not 
participated in the surgical procedure. Faecal continence was evaluated by using the 
Rockwood Fecal Incontinence Severity Index (RFISI). This index was assessed before 
and at 26 weeks after the procedure.
statistical analysis
Fisher’s exact probability test was used. The limit of statistical significance was set at 
P = 0.05.
results
Primary fistula healing was observed in 18 (82%) patients. Four patients presented 
with persisting discharge at the intersphincteric wound after the external component 
of their fistula had healed. This conversion to a low intersphincteric fistula enabled 
simplified subsequent fistulotomy without division of the lower part of the external 
anal sphincter. This second procedure was successful in all four patients, finally result-
ing in an overall healing rate of 100%. The median duration of follow-up was 19.5 
(3-35) months. The median time period to the second procedure was 5 (5-7) months. 
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The relatively large proportion (41%) of female patients was striking. This observation 
suggests that low transsphincteric fistulae occur more frequently in women than high 
transsphincteric fistulae. In almost all (91%) patients the internal opening was located 
anteriorly in the midline. This location was found in eight of the nine female patients. 
All female patients showed primary and complete fistula healing (Table 1). The RFISI 
was filled in by all patients. Prior to LIFT, the median RFISI was 0 (0-20). Six months 
after the last procedure, it had not changed significantly, 0 (0-10). The RFISI after LIFT, 
resulting in primary fistula healing, was found to be improved in two patients and 
deteriorated in none of the others. In the four patients in whom the transsphincteric 
fistula was converted into an intersphincteric fistula, the RFISI did not deteriorate 
after subsequent fistulotomy. In the eight female patients in whom the internal fistula 
opening was located anteriorly in the midline, the median preoperative RFISI was 0 
(0-0) and the median postoperative RFISI was 0 (0-0).
discussioN
Fistulotomy is the only fistula treatment that actually works most of the time.1,2 For pa-
tients with a high transsphincteric fistula, passing through the upper or middle third of 
the external anal sphincter, fistulotomy is not appropriate because of the high risk of 
faecal incontinence.2-4 Fortunately there are sphincter-preserving alternatives such as 
flap repair, the use of glue and plugs and LIFT.16 These sphincter-preserving techniques 
are not applied in the treatment of low transsphincteric fistulae. For patients with a 
fistula passing through the lower third of the external anal sphincter, fistulotomy is 
still advocated as the treatment of choice, because it is considered a simple, effective 
and safe procedure with a minimal risk of incontinence. However, there are indications 
that impairment of faecal continence is more common than thought. In a recent 
study, Bokhari and Lindsey17 observed major and minor incontinence after fistulotomy 
for low fistulae in 5% and 11% of their patients. They found even higher percent-
Table 1. Primary and secondary healing after ligation of the intersphincteric fistula tract
Patient and fistula characteristics Primary healing (N=18) Secondary healing (N=4)
Median age (years) 45.5 43.5
Male:female ratio 9:9 4:0
One or more previous attempts at repair 10 0
Preoperative seton drainage 5 1
Location of the internal opening (%)
Posterior 11 0
Anterior 89 100
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ages in patients presenting with one or more of the following compromising factors: 
anterior fistula in females, pre-existing incontinence, diminished squeeze pressures, 
sphincter defects on anal ultrasound, previous anal surgery and at-risk obstetric his-
tory. Garcia-Aguilar et al. reported major and minor incontinence after fistulotomy 
for low transsphincteric fistulae in 44% of their patients. They also found that female 
gender and an internal opening located in the midline anteriorly were predictive 
factors of impaired continence after fistulotomy.4 Female patients are probably at 
risk because they have a shorter external anal sphincter, which is prone to damage 
during childbirth.6,7 The incidence of impaired continence after fistulotomy for low 
anal fistula has been addressed in mostly retrospective studies.2,4,17-20 In most of these 
studies impairment of continence was assessed by simple questionnaires and not with 
validated faecal incontinence grading scores. Manometric data and imaging details re-
garding the exact course of the fistula tract are generally lacking and remarkably often 
no distinction is made between intersphincteric and low transsphincteric fistulae. The 
question is whether this distinction is important or not. Atkin et al.20 found no differ-
ence in the operation-induced continence disturbances after division of the internal 
anal sphincter alone during fistulotomy for intersphincteric fistulae compared with 
division of the lower part of both anal sphincters in patients with a transsphincteric 
fistula. In contrast to this finding, Garcia- Aguilar et al.4 observed that the rate of 
incontinence increased linearly with the estimated amount of external anal sphincter 
divided during fistulotomy. Cavanaugh et al.21 demonstrated by linear regression that 
only the amount of external anal sphincter divided correlated with faecal incontinence 
severity index scores. Based on these findings it seems likely that division of the in-
ternal anal sphincter alone is less detrimental than division of both anal sphincters. 
Although the exact incidence of impaired continence after fistulotomy for low trans-
sphincteric fistula cannot be assessed, the data obtained from the studies conducted 
so far suggest that continence disturbances are more common than thought after 
surgical treatment of low fistulae (Table 2). A recent study conducted by Ellis revealed 
that anal sphincter preservation is the primary concern of most patients. His findings 
indicate that, within limits, minimizing the risk of diminished continence is of greater 
importance for most patients than the success rate of the surgical procedure.8 Given 
these findings patients with a low transsphincteric fistula would also be eligible for a 
sphincter-preserving alternative instead of a conventional fistulotomy. LIFT has been 
introduced as a promising sphincter-preserving alternative to flap repair for high trans-
sphincteric fistula, passing through the middle or upper third of the external anal 
sphincter. The LIFT procedure is based on an original concept regarding eradication 
of the fistulous disease at its origin without sphincter damage. Rojanasakul25 was the 
first to describe this new technique. He observed primary fistula healing in 94% of 
his patients. Other reports from Malaysia and Singapore also revealed high healing 
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5rates, exceeding those obtained with the current sphincter-saving techniques.11,15 
However, recent reports from the USA and Australia indicated that LIFT fails in one of 
every three patients.9,12,13 Based on these promising results we questioned whether 
LIFT could be a good alternative for conventional fistulotomy in patients with a low 
transsphincteric fistula. The outcome of the present study, with a primary healing rate 
of 82%, illustrates that LIFT is indeed a good alternative for fistulotomy. In all these 
patients both anal sphincters could be preserved. In the four (18%) patients without 
primary healing, the external component of the fistula healed and persistent discharge 
occurred only at the intersphincteric wound. Such conversion to an intersphincteric 
fistula has also been reported by others.9,12-15 This phenomenon suggests that LIFT 
is sufficient on the side of the external anal sphincter but not always on the side of 
the internal anal sphincter, resulting in ongoing inflammation in the intersphincteric 
plane in approximately one of six patients. A recent study, conducted in our hospital, 
revealed that the intersphincteric track in most perianal fistulae is lined with granula-
tion tissue. The presence of granulation tissue may be suggestive of an inflammatory 
process.26 Conversion to an intersphincteric fistula due to ongoing intersphincteric 
disease requires a second procedure including division of the lower part of the internal 
anal sphincter. This could be considered a disadvantage of the LIFT procedure, with a 
potential risk of continence disturbance. After fistulotomy for intersphincteric fistula 
continence disturbance has been reported in up to 38% of cases.23 However, in our 
four patients who underwent a second procedure with division of the lower part of 
the internal anal sphincter, the RFISI did not change. Since the second procedure was 
successful in all our four patients, the overall healing rate was 100%. In both patients 
with primary healing and patients with secondary healing, the external anal sphincter 
could be preserved in all cases. This, in our opinion, is the great advantage of the 
Table 2. Impairment of faecal continence after fistulotomy for low anal fistula
Postoperative incontinence*
Author Year N Minor (%) Major (%) Minor and/or 
Major (%)
Garcia-Aguilar et al.4 1996 177 39
Mylonakis et al.22 2001 65 9 0
Westerterp et al.2 2003 18 44 0
Chang and Lin.23 2003 45 38
Van der Hagen et al.18 2006 62 5 0
Toyonaga et al.24 2007 148 20
Van Koperen et al.19 2008 63 41 5
Bokhari and Lindsey.17 2010 53 11 5
Atkin et al.20 2011 51 23 2
*Minor incontinence is incontinence for gas and/or soiling. Major incontinence is incontinence for solid 
and/or liquid stool.
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LIFT procedure for patients with a low transsphincteric fistula. The median RFISI did 
not deteriorate after LIFT, not even after the second procedure with division of the 
lower part of the internal anal sphincter. Furthermore, the present study revealed two 
striking features of low transsphincteric fistulae: first, the relatively large proportion of 
female patients, suggesting that low transsphincteric fistulae occur more frequently 
in women than high transsphincteric fistulae; and second, the location of the internal 
fistula opening with a predilection for the anterior midline. Female patients with an 
anterior fistula in particular are at risk for impaired continence after fistulotomy.4,17 
None of our female patients encountered deterioration of continence after LIFT. LIFT is 
an attractive alternative to avoid fistulotomy. It seems likely that division of the lower 
part of the external anal sphincter is no longer necessary in the treatment of low 
transsphincteric fistulae.
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AbstrAct
background
Intersphincteric fistulas with a high upward extension, up to or above the level of the 
puborectal muscle, in the intersphincteric plane are rare. Most of these fistulas have 
no external opening and they are frequently associated with a high intersphincteric 
and/or supralevator abscess. Division of a large amount of internal anal sphincter by 
extended fistulotomy has a potential risk of diminished fecal continence. The aim of 
this study was to evaluate flap repair combined with drainage of associated abscesses 
in high intersphincteric fistulas.
method
Fourteen patients with a cryptoglandular fistula with high intersphincteric extension 
were included. Transanal advancement flap repair combined with intersphincteric and/
or extrasphincteric drainage of associated abscesses was performed. Preoperatively, 
patients underwent endoanal MRI.
results
In 1 patient the fistula was not associated with an abscess. In 10 patients the fistula 
tract ended in a high intersphincteric abscess. Three patients presented with a high 
intersphincteric abscess and a supralevator abscess. Primary healing was observed 
in 79% of the patients. The 3 patients without primary healing had a supralevator 
abscess. In these patients, healing was obtained after a second, third, and fourth 
procedure. The overall healing rate was 100%. Median postoperative Rockwood 
score was 0 (range, 0-15).
conclusion
Since most high intersphincteric fistulas have no external opening and are frequently 
associated with abscesses, preoperative imaging is useful. Flap repair with adequate 
drainage of the abscesses is successful, except in fistulas with supralevator extension. 
However, healing may be achieved by additional procedures.
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iNtroductioN
In 1967, Parks et al1 introduced a classification of anal fistulas based on the course 
of the fistula in relation to the anal sphincters. They defined 4 main types of fistulas, 
intersphincteric, transsphincteric, suprasphincteric, and extrasphincteric. Intersphinc-
teric fistulas are the most common.1,2 The majority of these fistulas have a short 
downward extension in the intersphincteric plane to their external opening near the 
anal verge and can be treated successfully by lay open fistulotomy.3,4 In exceptional 
cases, intersphincteric fistulas lack an external opening and exhibit a high upward 
extension, up to or above the level of the puborectal muscle, in the intersphincteric 
plane and are frequently associated with a high intersphincteric and/or supralevator 
abscess (Fig. 1).1 To lay open these high intersphincteric fistulas adequately, division 
of a large amount of the internal anal sphincter is required,5-7 with a potential risk 
of diminished fecal continence. To our knowledge no reports are available regarding 
sphincter-preserving alternatives for the treatment of high intersphincteric fistulas. 
The purpose of the present study was to evaluate whether these rare fistulas can 
be treated adequately by transanal advancement flap repair (TAFR) with subsequent 
drainage of associated abscesses.
Figure 1. Illustration of high intersphincteric fistulas
These fistulas have no external opening, extend upwards in the intersphincteric space, and end in a high 
intersphincteric and/or supralevator abscess. R = rectum; PRM = puborectal muscle; EAS = external anal 
sphincter; IAS = internal anal sphincter; IA = intersphincteric abscess; SA = supralevator abscess.
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method
study design
Fourteen patients with a high intersphincteric fistula were selected from a database of 
277 patients who underwent TAFR in our institution between March 1995 and Febru-
ary 2011. Patients with Crohn’s disease were excluded from this study. Before the 
procedure, patients underwent endoanal MRI (EA MRI) to visualize the course of the 
fistula tract and to determine the presence and location of associated abscesses. All of 
the patients provided informed consent, meeting the standards set by the institutional 
review board of the hospital. All of the operations were performed by 1 surgeon 
(W.R.S.). Patients were treated in day-care setting.
endoanal mri
All of the EA MRI examinations were performed with the use of an endoanal coil with 
a 1.5-T magnetic resonance imager (Gyroscan NT Intera 1.5, Philips Medical Systems, 
Best, the Netherlands). The endoanal coil (Philips Medical Systems) consisted of a fixed, 
rectangular, 60-mm—long rigid receiver coil with a width of 16 mm. In each patient, 
the following 3 sequences were used. Transverse T2-weighted, contrast-enhanced, 
fast field-echo imaging was performed. Transverse T2-weighted, fast spin echo MRI 
was performed with and without fat saturation. Coronal and sagittal T2-weighted 
spin echo MRI was performed without fat saturation. All of the EA MRIs were evalu-
ated by 1 radiologist at our institution.
surgical techniques
Transanal advancement flap repair
Patients underwent complete mechanical bowel preparation (polyethylene glycol, 
Klean-Prep, Helsinn Birex Pharmaceuticals, Dublin, Ireland). After induction of general 
endotracheal anesthesia, metronidazole (500 mg), together with cefuroxime (1500 
mg), was administered intravenously. The patient was placed in prone jackknife posi-
tion with the buttocks taped apart. Initially a Park’s retractor (Park’s Anal Retractor, 
Slidell, LA ) was used to expose the internal opening of the fistula. Since 2003, a 
Lone Star retractor has been used for this purpose (Lone Star Retractor System, Lone 
Star Medical Products, Inc, Houston, TX). The internal opening was enlarged and the 
remaining crypt-bearing tissue was excised. A small rim of the anodermis, below the 
internal opening, was excised to create a neodentate line. The defect in the internal 
anal sphincter was closed with absorbable sutures 2/0 Vicryl (Ethicon, Inc, Somerville, 
NJ). A flap consisting of mucosa, submucosa, and some of the most superficial fibers of 
the internal anal sphincter was raised from the level of the dentate line and mobilized 
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over a distance of 4 to 6 cm proximally. The flap was advanced and sutured to the 
neodentate line with absorbable sutures 2/0 monocryl (Ethicon, Inc, Somerville, NJ).
Intersphincteric drainage
A curvilinear incision was made just outside the intersphincteric groove. Dissection 
was continued in the intersphincteric plane until the abscess was encountered. The 
tip of a mushroom drain (size 12 Fr (4 mm), Coloplast, Humlebaek, Denmark) was 
positioned within the abscess cavity. The drain was fixed at the perianal skin with 
nonabsorbable sutures (3/0 Ethilon, Ethicon, Inc, Norderstedt, Germany).
Extrasphincteric drainage
An incision was made in the posterior midline, a few centimeters from the anal verge. 
Dissection was continued into the deep postanal space. The supralevator abscess cav-
ity was entered through the pelvic floor muscle, and the tip of a mushroom drain (size 
12 Fr (4 mm), Coloplast) was positioned in cavity. The drain was fixed at the perianal 
skin with nonabsorbable sutures (3/0 Ethilon, Ethicon, Inc, Norderstedt, Germany).
Postoperative care
All of the patients were prescribed a stool softener for 2 weeks. There was no diet 
restriction. Patients were instructed to flush the drain 3 times per day until removal 
and to take a sitz bath 2 to 3 times daily until the wound was healed. After discharge, 
patients were advised to restrict physical activity for 2 weeks. The drain was removed 
during the first visit at outpatient clinic, ≈2 weeks after surgery.
data recording and follow-up
Patient visits were scheduled 2 weeks, 8 weeks, and 6 months after surgery. Healing of 
the fistula was defined as complete wound healing with absence of symptoms. Patient 
and fistula characteristics were collected from medical charts. Follow-up information 
regarding fistula recurrence and fecal continence was obtained from medical charts 
and a follow-up telephone call. The postoperative fecal continence was assessed by 
using the Rockwood Fecal Incontinence Severity Index.
statistical analysis
Data were analyzed by use of SPSS-IBM software version 20.0 for Windows (SPSS Inc, 
Chicago, IL).
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results
The baseline patient and fistula characteristics are presented in Table 1. Nine patients 
(64%) had undergone ≥1 previous surgical attempt at repair before referral. Before 
TAFR, EA MRI was performed in all of the patients except 1, in whom this type of 
imaging was not possible because of the presence of a pacemaker. The high upward 
extension of the fistula tract and the presence of associated abscesses were confirmed 
during surgery in all 13 of the patients in whom EA MRI was performed. The internal 
opening of the fistula was located at the posterior midline in 13 patients. In 1 female 
patient the internal opening was located anteriorly. In all of the patients except 1, 
associated abscesses were identified. In 10 patients, the intersphincteric fistula tract 
ended in an abscess, located at the level of the puborectal muscle (Fig. 2A). The 
remaining 3 patients presented with both a high intersphincteric abscess and a 
satellite supralevator abscess (Fig. 2B). In 6 patients, intersphincteric horseshoeing 
was identified (Fig. 2C). In only 2 of the 14 patients was an external fistula opening 
detected. In both cases this opening was located at the posterior midline, near the 
anal verge. Details of the surgical procedures and healing pattern are presented in 
Table 2. All of the patients underwent a TAFR. In 12 patients this procedure was 
performed with concomitant drainage of associated abscesses by an intersphincteric 
or an extrasphincteric approach. In 1 patient no abscess was identified, and in 1 
patient the abscess was found to be dissolved during surgery. Primary healing was 
observed in 11 patients (79%). In the 3 patients without primary healing, the fistula 
was associated with a supralevator abscess. In 1 patient with complete healing of 
Table 1. Baseline patient and fistula characteristics
Baseline patient and fistula characteristics n
Median age, years (range) 41 (26-71)
Sex ratio (male:female) 12:2
Previous surgical attempt at repair before referral 9
Preoperative seton drainage 2
Location of the internal opening
Posterior 13
Anterior 1
Previous EA MRI 13
EA MRI
IA 5
IA and HS 5
IA and SA 2
IA, SA and HS 1
EA = endoanal; IA = intersphincteric abscess; SA = supralevator abscess; HS = horseshoeing.
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the flap, second and third drainages were necessary to obtain healing. In 2 patients, 
a second TAFR with drainage was performed. This was successful in 1 patient. In the 
other patient the abscesses persisted, and third and fourth drainages were necessary 
to obtain healing. The overall healing rate was 100%. Median follow-up was 85.5 
months (range, 20-211 months). None of the patients encountered incontinence for 
solid and/or liquid stool after their final treatment. However, in 6 patients minimal 
Table 2. Surgical management and healing
Surgical management and healing Success (n) Failure (n)
First intervention
TAFR and IS drain (n = 10) 8 2
TAFR and ES drain (n = 2) 1 1
TAFR (n = 2) 2 0
Second intervention
TAFR and IS drain (n = 1) 1 0
TAFR and ES drain (n = 1) 0 1
IS drain (n = 1) 0 1
Third intervention
IS drain (n = 1) 0 1
ES drain (n = 1) 1 0
Fourth intervention
IS and ES drain (n = 1) 1 0
TAFR = transanal advancement flap repair; IS = intersphincteric; ES = extrasphincteric.
Figure 2. Endoanal MRI of a high intersphincteric fistula with horseshoeing in the intersphincteric plane 
and associated high intersphincteric and supralevator abscesses
A, The high intersphincteric abscess (IA; indicated by arrows) shows hyperintense signal on the sagittal 
T2-weighted spin echo (SE) image. B, The supralevator abscess (SA; indicated by dots) shows hyperin-
tense signal on the coronal T2 weighted SE image. C, The horseshoeing (HS; indicated by arrows) shows 
high signal intensity on the transverse T2-weighted fast SE image.
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postoperative incontinence to flatus and/or soiling was observed. None of the patients 
used pads. The median postoperative fecal continence score was 0 (range, 0-15).
discussioN
Most intersphincteric fistulas extend downward in the intersphincteric plane to the 
perianal skin. Their external opening is located close to the anal verge. Occasionally, 
intersphincteric fistulas extend upward, up to or above the level of the puborectal 
muscle.1 These rare fistulas often lack an external opening and are frequently associat-
ed with intersphincteric and/or supralevator abscesses (Fig.1). Reviewing 400 patients 
with a perianal fistula, Parks et al1 identified a high intersphincteric fistula in only 20 
cases (5%). In the present study, 14 patients (5%) have been selected from a database 
of 277 patients who underwent a TAFR in our institution. The low incidence of these 
fistulas may be the reason that studies regarding their treatment are scarce. Lay open 
fistulotomy is the treatment of choice for patients with a simple intersphincteric fis-
tula.3,4 However, this procedure may not appropriate for high intersphincteric fistulas. 
To lay open these fistulas sufficiently, division of a large amount of the internal anal 
sphincter is required. Although lay open fistulotomy of simple intersphincteric fistulas 
is considered a safe procedure, minor continence disturbances still occur, as reported 
by Toyonaga et al.8 and Chang and Lin.9 It seems likely that lay open fistulotomy in 
patients with a high intersphincteric fistula is associated with an increased risk of 
disturbed continence, because a larger portion of the internal anal sphincter must 
be divided. Therefore, a sphincter-preserving technique is preferred. Reviewing the 
literature, no data have been found regarding sphincter-preserving treatment of high 
intersphincteric fistulas. Therefore, we conducted the present study to assess the role 
of TAFR with concomitant drainage of associated abscesses in the treatment of these 
fistulas. The primary healing rate of 79% illustrates that flap repair combined with ad-
equate drainage of associated abscesses is a good treatment option for patients with 
a high intersphincteric fistula. In the 3 patients without primary healing, a supraleva-
tor abscess was present. This observation suggests that extension of the fistula tract to 
above the level of the pelvic floor prohibits primary healing after flap repair. However, 
in these patients healing may also be achieved by additional drainage. This resulted 
in an overall healing rate of 100%. None of the patients reported major incontinence 
after their final treatment. The median postoperative fecal continence score was 0 
(range, 0-15). In several studies it has been demonstrated that preoperative imaging 
reveals essential information, especially in patients with a complex fistula.10-12 In the 
present study, the external fistula opening was absent in 12 patients, and visible signs 
of associated abscesses were lacking. Although associated abscesses can be palpated 
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during surgical exploration in some cases, the exact location of these abscesses is 
very difficult to pinpoint by palpation alone. Since preoperative EA MRI revealed an 
associated abscess in 13 patients, we believe that appropriate preoperative imaging 
is helpful. In the present study, EA MRI provided essential information and guided the 
surgical procedure, especially regarding the approach of associated abscesses and the 
identification of intersphincteric horseshoe extension. Based on our experience, we 
recommend adequate preoperative imaging, which is useful for the correct diagnosis 
and appropriate treatment of fistulas with a high intersphincteric and/or supralevator 
extension. The limitations of this study are the retrospective nature and the lack of 
data regarding preoperative fecal continence. Strengths of the study are the unique 
series of patients with a rare type of fistula, long median follow-up, and preopera-
tive imaging in all of the patients. The present case series shows that preoperative 
imaging is useful in high intersphincteric fistulas. TAFR with concomitant drainage of 
associated abscesses is successful, except in the fistulas with a supralevator extension. 
However, in these patients healing may also be achieved by additional drainage.
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AbstrAct
background
At present, transanal advancement flap repair (TAFR) is the treatment of choice for 
transsphincteric fistulas passing through the upper and middle third of the external 
anal sphincter. It has been suggested that epithelialization of the fistula tract contrib-
utes to the failure of the treatment. The aim of this study was to assess the prevalence 
of epithelialization of the fistula tract and to study its effect on the outcome of TAFR 
and TAFR combined with ligation of the intersphincteric fistula tract (LIFT).
method
Forty-four patients with a high transsphincteric fistula of cryptoglandular origin un-
derwent TAFR. Nine of these patients underwent a combined procedure of TAFR with 
LIFT. In all patients the fistula tract was excised from the external opening up to the 
outer border of the external anal sphincter. In patients undergoing TAFR combined 
with LIFT an additional central part of the intersphincteric fistula tract was excised. 
A total of 53 specimens were submitted. Histopathological examination of the speci-
mens was carried out by a pathologist, blinded for clinical data.
results
Epithelialization of the distal and intersphincteric fistula tract was observed in only 25 
and 22% of fistulas, respectively. There was no difference in outcome between fistulas 
with or without epithelialization.
conclusion
Epithelialization of high transsphincteric fistulas is rare and does not affect the out-
come of TAFR and TAFR combined with LIFT.
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iNtroductioN
The main objective in the treatment for fistulas, passing though the upper or middle 
third of the external anal sphincter, is healing of the fistula without subsequent dam-
age to both sphincters. Although transanal advancement flap repair (TAFR) provides 
a useful tool for achieving this goal, fistula healing fails in one out of every three 
patients.1-8 Several studies have been conducted to identify factors affecting the out-
come of TAFR. However, until now, no definite factor predisposing to failure has been 
determined. In 1995, Lunniss et al.9 observed epithelium lining the intersphincteric fis-
tula tract in 13 out of 18 patients with a low perianal fistula. Though the effect of this 
epithelialization on fistula healing was not assessed, the authors stated that this might 
be a cause for the persistence of the fistula. This hypothesis is still generally accepted, 
and this study is cited in many papers and text books.10-13 Recently Van Koperen et 
al.14 also assessed the presence of epithelium in fistula tracts. In 18 patients with a low 
transsphincteric fistula they took biopsies at three different locations, on the side of 
the internal opening, in the middle of the fistula tract, and near the distal end close to 
the external opening. Epithelium was predominantly found near the internal opening. 
In the other parts of the fistula tract, epithelialization was found to be rare. According 
to these authors epithelialization might contribute to the failure of healing, although 
they did not provide evidence for this statement. The aim of the present study was to 
assess the prevalence of epithelialization of the fistula tract and to study the effect of 
epithelialization on the healing rate.
method
Between June 2008 and December 2009, 44 consecutive patients were enrolled in 
this study. The series comprised 30 men and 14 women. Median age at the time of 
repair was 46 years (range, 21-67 years). Median time interval since the onset of the 
fistula was 17 months (range, 5-73 months). Two patients underwent preoperative 
seton drainage for at least 2 months, until the day of the flap repair. Forty patients 
underwent a primary intervention, and 4 patients underwent secondary intervention 
after previous TAFR. In all patients the fistula tract crossed the upper or middle third 
of the external anal sphincter. All operations were performed by one surgeon (W.R.S.). 
Between June 2008 and January 2009, 35 patients underwent TAFR. In February 2009 
ligation of the intersphincteric fistula tract (LIFT) was added to flap repair. In all patients 
the fistula tract was excised from the external opening up to the outer border of the 
external anal sphincter. In the nine patients who underwent a combined procedure, 
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the central part of the intersphincteric fistula tract was also harvested. A total of 53 
specimens were submitted for histopathological examination.
exclusion criteria
Patients with a rectovaginal fistula or a fistula due to Crohn’s disease were excluded 
from the present series.
Preoperative
Patients underwent complete mechanical bowel preparation (polyethylene glycol: 
Klean-prep Helsinn Birex Pharmaceuticals, Dublin, Ireland). After induction of general 
endotracheal anesthesia, metronidazole (500 mg) together with cefuroxime (1,500 
mg) was administered intravenously.
operative technique tAfr
After the patient was placed in the prone jackknife position, the external opening was 
enlarged. The fistula tract was excised as far as possible, up to the outer border of the 
external anal sphincter and submitted for histopathological examination. The internal 
opening of the fistula was exposed using a Lone Star retractor (Lone Star Retractor 
System, Lone Star Medical Products, Inc. Houston, TX, USA). The crypt-bearing tissue 
around the internal opening as well as the overlying anodermis was then excised. The 
fistula tract was cored out of the sphincters. The defect in the internal anal sphincter 
was closed with absorbable sutures. A flap consisting of mucosa, submucosa and 
some of the most superficial fibers of the internal anal sphincter was raised from the 
level of the dentate line and mobilized over a distance of 4 to 6 cm proximally. The flap 
was advanced and sutured to the neodentate line with absorbable sutures.
operative technique lift
With the patient in the prone jackknife position, a probe was introduced into the 
fistula tract. A curvilinear incision was made in the intersphincteric groove, and the 
fistula tract was identified with the probe in situ. Care was taken not to injure the 
anal sphincters. After the dissection of the fistula tract, the probe was removed. The 
intersphincteric fistula tract was ligated near the internal and external anal sphincters. 
The central part of the intersphincteric fistula tract was excised and submitted for 
histopathological examination. Finally, the wound in the intersphincteric groove was 
closed with non-absorbable sutures.
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Postoperative
All patients were immobilized for 5 days. All patients received a clear liquid diet for 
5 days. During this time period, metronidazole and cefuroxime were administered 
intravenously three times daily.
histopathological examination
After fixation in 10% formalin, the 53 specimens were cut in sections. These sections 
were strained using the routine hematoxylin and eosin staining method. Pan keratin 
antibodies were used for the detection of keratins, which are intermediate filament 
proteins expressed mainly in epithelial cells. The histopathological examination of the 
fistula tract was carried out by a pathologist, blinded for clinical data.
statistical analysis
Comparison of the changes between groups was conducted using the Fisher’s exact 
probability test. The limit of statistical significance was set at P = 0.05.
results
Median follow-up was 11 months (range, 6–13 months). The healing rate after surgery 
was 68%. In the fistula tracts extending from the external opening up to the outer 
border of the external anal sphincter, epithelialization was observed in 11 specimens 
(25%). In 5 of these patients the fistula tracts were completely lined with epithelium 
(Fig. 1), while in 6 patients the specimens were only partly lined with epithelium 
(Fig. 1). In the other specimens (75%) granulation tissue was observed (Fig. 1). In the 
intersphincteric fistula tract epithelium lining was observed in 2 specimens (22%). In 
both specimens the epithelial lining was complete. The fistula tract extending from 
the external opening up to the outer border of the external anal was also completely 
lined with epithelium in these 2 patients. In the other specimens (78%) the fistula 
tract was lined with granulation tissue. No anal gland tissue with mucin-producing 
cells could be detected in any of the patients. There was no difference in healing rate 
Figure 1. From left to right, complete epithelial lining, incomplete epithelial lining and granulation tissue
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between fistulas with or without epithelialization, as shown in Table 1. We found no 
correlation between either the time interval since onset of the fistula or prior seton 
drainage, and the presence of epithelium.
discussioN
Transanal advancement flap repair provides a useful tool for the treatment of high 
transsphincteric fistulas. Recent studies indicate that this procedure fails in one of 
the every three patients. Potential risk factors for failure, such as gender, age, body 
mass index, prior attempts at repair, rectal mucosal blood flow and previous use of a 
seton, have been analyzed.15,16 Until now, no definite risk factor for failure has been 
identified. In the present study, similar healing rates were observed in patients with 
and those without epithelialization of their fistula tract. This finding indicates that 
epithelialization does not affect the outcome of TAFR and TAFR combined with LIFT. In 
1995, Lunniss et al.9 were the first to describe the epithelialization of perianal fistulas. 
They observed epithelium lining in 13 out of 18 patients. However, they did not men-
tion whether the fistula tract was completely or partly lined with epithelium. Though 
the effect of epithelialization on fistula healing was not assessed, the authors stated 
that epithelialization might contribute to the persistence of fistulas. This hypothesis is 
still generally accepted, despite the lack of evidence.17,18 Recently, Van Koperen et al.14 
examined the presence of epithelium in fistula tracts. In 18 patients with a low trans-
sphincteric fistula they took biopsies from the fistula tract from 3 different locations, 
at the side of the internal opening, in the middle of the fistula tract, and near the 
distal end close to the external opening. At the side of the internal opening, epitheli-
alization was observed in the majority of patients. In our opinion this epithelium does 
not represent epithelialization of the fistula tract since it is most likely derived from 
the epithelium lining of the crypts of Morgagni and the anal glands. Epithelialization 
was observed in 4 biopsies taken from the middle of the fistula tract and in only 2 
biopsies taken from the distal end close to the external opening. These latter findings 
are almost similar to those obtained from the present study. Though epithelializa-
Table 1. Overview of results based on presence or absence of epithelialization
Epithelialization No-epithelialization P-value
Number of patients 11 33
Age (years) 42 48 0.42
Gender (% male) 64 70 0.68
Time interval since onset 19 16 0.43
Healing rate (%) 64 70 0.55
Identification of epithelialization in high transsphincteric fistulas 85
7
tion was observed almost exclusively near the internal opening and only a few fistula 
tracts were completely epithelialized, Van Koperen et al. stated that epithelialization 
of fistula tracts is present in most patients and might contribute to failure. In our 
opinion their study does not provide evidence for the adverse effect of epithelializa-
tion on fistula healing. Kiehne et al. compared squamous epithelium, obtained from 
perianal fistulas, with perianal skin and rectal mucosa. They found that the epithelial 
lining of fistulas expresses identical cytokeratins and similar levels of antimicrobial 
peptides as perianal skin. Based on this finding, they suggested that epithelialization 
of perianal fistulas starts at the side of the external opening and serves as a defense 
mechanism to prevent local and systemic infection by microbes from fecal material 
passing through the fistula tract.19 According to these authors, epithelium growth 
in perianal fistulas is a late event. However, they did not assess the time interval 
between the onset of fistula development and the beginning of epithelialization. In 
the present study the median time interval since the onset of fistula development 
did not differ between patients with and without epithelial lining of their fistula. It 
is not known why epithelialization does not occur in every fistula at the same stage. 
It has been suggested that perpetuation of inflammation prevents the migration and 
arrangement of myofibroblasts, which are the key cells in the events of tissue repair.20 
These cells are able to form a new basement membrane, which is a prerequisite for 
the migration of epithelial cells. In the present study epithelialization of the distal and 
intersphincteric fistula tracts was found in only 25 and 22% of fistulas, respectively. 
The lack of epithelialization in the majority of our patients may be an expression of 
ongoing inflammation. Based on this assumption, one would expect a worse outcome 
after flap repair in patients without epithelialization of their fistula. However, in the 
present study similar healing rates were found in patients with and those without 
epithelial lining. Based on this observation, it seems obvious that epithelialization, like 
many other factors, does not adversely affects the outcome of flap repair. In a previous 
study we assessed the outcome of repeat flap repair in patients, who encountered a 
failure after the initial procedure. In all patients we noticed complete healing of the 
flap, except at the site of the original internal opening.21 This remarkable finding 
does suggest that ongoing inflammation in the remaining fistula tract contributes to 
persistence of the fistula. Further studies are warranted to examine the microbiologic 
and immunologic characteristics of this inflammatory process.
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Assessment of microbiota 
and peptidoglycan in perianal 
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AbstrAct
background
Transanal advancement flap repair has been advocated as the treatment of choice for 
high transsphincteric perianal fistulas, but fails in 1 of every 3 patients. Persistence of 
the fistula after flap repair might be the result of ongoing disease in the remaining 
fistula tract.
method
In 10 specimens of the distal part of the fistula, microbiota was assessed by means of 
conventional microbiological culture and 16S rRNA gene sequencing. Pro-inflamma-
tory bacterial peptidoglycan and recognition proteins were assessed by immunohis-
tochemistry.
results
Bacterial species were bowel derived, skin derived, or a combination of both. No 
mycobacterium species were identified. 16S rRNA gene sequencing failed to identify 
bacteria in all but 1 specimen, most likely as a result of low numbers of organisms. 
Peptidoglycan was detected in 90% of the patients, and a host response to peptido-
glycan in 60%.
conclusion
We suggest that peptidoglycan might play a role in the ongoing inflammation in 
perianal fistulas.
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iNtroductioN
Transsphincteric fistulas passing through the lower third of the external sphincter can 
be easily treated by either classic laying open (fistulotomy) or excision (fistulectomy). 
These procedures provide excellent healing rates and a minimal risk of postoperative 
incontinence.1 However, transsphincteric fistulas passing though the upper or middle 
third of the external anal sphincter are a notorious condition. Fistulotomy or fistulec-
tomy will result in unacceptable continence disturbances in these cases. Therefore, 
sphincter-saving techniques have been developed. Despite new treatment modalities 
such as application of fibrin glue or the use of an anal fistula plug, transanal ad-
vancement flap repair (TAFR) remains the treatment of choice for patients with high 
transsphincteric fistulas.2 This procedure is successful in 2 of every 3 patients.3 Until 
now no definite factor predisposing to failure has been identified. A previous study 
conducted in patients with a persistent fistula after TAFR revealed complete healing of 
the flap, except at the site of the original internal opening.4 This observation and the 
lack of factors predisposing to failure suggest that persistence of the fistula is caused 
by ongoing disease in the remaining fistulous tract. Inflammation seems to be an 
important part of the pathogenesis of perianal fistulas. A recent study, conducted in 
our hospital, revealed that most perianal fistulas are lined with granulation tissue.5 The 
presence of granulation tissue in the fistulous tract is suggestive of an inflammatory 
process. Some authors studied the bacteriology of perianal fistulas of cryptoglandular 
origin.6,7,8 Their reports failed to demonstrate pathogenic bacteria. Moreover, only 
low numbers of organisms were found, suggesting that permanent infection is not a 
major contributing factor to the persistence of perianal fistulas. However, these data 
were obtained only with the use of conventional culture techniques. These cultures 
require viability of the bacteria for which accurate handling of the clinical material is 
essential. It might be that bacteria died due to inadequate sample processing. Fur-
thermore, conventional culture techniques are largely dependent on the type and 
range of media used. Modern molecular techniques that target bacterial 16S rRNA 
offer alternative and more sensitive means for the study of bacterial flora.9,10 For this 
technique, the viability of strains is not required and even dead bacterial species can 
still be reliably identified. Live bacteria as well as inflammatory bacterial remnants 
could potentially contribute to the ongoing inflammation in the remaining fistula 
tract. Studies on the pathogenesis of different chronic inflammatory diseases, such 
as Crohn’s disease, show that peptidoglycan (PG) is a powerful effector stimulating 
inflammation.11,12 PG is a major component of the Gram-positive and Gram-negative 
bacterial cell wall, providing structural strength and allowing bacteria to resist osmotic 
pressure. Presence of PG in tissues and intracellularly in phagocytes can be assessed 
by immunohistochemical analysis, using monoclonal antibodies. The aim of this pilot 
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study was to address the hypothesis of chronic infection and bacterial remnants in 
persisting perianal fistulas by assessing the presence of bacteria in the fistula tract by 
means of 16S rRNA gene sequencing and pro-inflammatory bacterial PG detection. 
Furthermore, perianal fistulas were studied in situ for a host response to PG.
method
A consecutive series of 10 patients with a cryptoglandular transsphincteric fistula 
passing through the upper or middle third of the external anal sphincter underwent 
TAFR. None of the patients used metronidazole and/or antibiotics prior to surgery. 
Forty percent of the patients had had previous surgical attempts. The present series 
comprised 8 males and 2 females. None of the patients had hepatitis B and/or HIV at 
the time of the study. Median age at time of repair was 48 years (range 28-56). The 
healing rate was 60. Clinical data are presented in Table 1. All patients provided in-
formed consent meeting the standards set by the hospital’s institutional review board.
exclusion criteria
Patients with a rectovaginal fistula or a fistula related to Crohn’s disease were excluded 
from the present series.
excision of the sample
With the patient in prone jack-knife position, the external opening was enlarged and 
the distal part of the fistula tract was excised as far as possible towards the outer 
border of the external anal sphincter. The outmost part of this tract was removed. The 
remaining fistula tract, containing the central part, was divided into 2 parts, of which 
1 was immediately stored in an anaerobic container and processed within 2 h. The 
second part was cryopreserved in liquid nitrogen and stored at −80 °C for process-
ing. After the excision of the fistulous tract, metronidazole (500 mg) together with 
cefuroxime (1500 mg) was administered intravenously and a TAFR was performed 
according to the previously described technique. A single surgeon performed all the 
procedures (WRS).
conventional microbiology
The samples were immersed in liquid growth media (including aerobic and anaerobic 
blood culture bottles) and were subjected to standard aerobic and anaerobic culture 
using various culture media including blood, McConkey, and Sauboraud agar plates 
in a routine and certified academic microbiological laboratory. After incubation, the 
media were examined by an experienced clinical microbiologist and pure cultures were 
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identified. In case of such pure cultures, the strains involved were stored for future 
use. In case of mixed cultures, the biomaterial was collected from the plate and stored 
in glycerol containing media for later use. After presumptive identification, pure 
cultures were analysed for precise species nature using Vitek technology and the API 
identification system. Vitek 2 (BioMérieux, Hazelwood, MO, USA) is a fully automated 
commercial microbial identification system. Culture for mycobacteria was performed 
using the MGIT960/BACTEC system (Becton Dickinson, Sparks, MD, USA).
16s rrNA sequencing
DNA extraction from the surgical material was piloted using a variety of methods. 
Employing small aliquots of an initial specimen, the optimal procedure was defined 
on the basis of DNA yield. Once the final protocol was established all specimens were 
treated similarly. DNA extracted from biopsies was amplified using general primers 
for the bacterial 16S rRNA genes. This involved broad-spectrum amplification of DNA 
from all bacterial species known and generated a mixture of polymerase chain reac-
tion (PCR) products.
immunohistochemical analysis
The presence of PG in the excised fistula tract was assessed by immunohistochemical 
analysis using 2 monoclonal antibodies (mAb). Monoclonal antibody 2E9 (mouse IgG3) 
was generated by immunization with human gut-derived peptidoglycan, and mAb 
15704 is a commercial anti-S. aureus PG IgG3 (QED Biosciences, San Diego, CA, USA). 
Monoclonal antibody 2E9 identifies cell wall fragments, the PG degradation product 
muramyl dipeptide, and lysozyme-solubilized cell walls of various Gram-positive bac-
teria. It is been suggested that 2E9 binds to the glycan backbone of PG.13 Furthermore, 
it has been described that 2E9 binds to the cell wall of S. epidermidis. The commercial 
Table 1. Clinical data
Subject Gender Age (years)
Internal opening 
fistula
External opening 
fistula
Outcome 
surgery
1 M 43 Anterior medial Right anterior lateral Success
2 M 54 Posterior medial Right Lateral Success
3 M 56 Posterior medial Right Lateral Success
4 F 31 Posterior medial Right Lateral Success
5 M 28 Posterior medial Posterior medial Failure
6 M 55 Anterior medial Left anterior lateral Failure
7 M 45 Posterior medial Posterior medial Failure
8 F 52 Anterior medial Left anterior medial Success
9 M 47 Anterior medial Right posterior medial Success
10 M 49 Posterior medial Left posterior medial Failure
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mAb anti-S. aureus PG IgG3 mAb 15704 especially identifies the peptidoglycan of S. 
aureus, protein A-negative S. aureus, and S. epidermidis. The host response to PG 
was examined by immunostaining with monoclonal antibodies against 2 of the 4 
PG recognition proteins (PGLYRP). We employed antibodies against PGLYRP1 (mAb 
188C424) and antibodies against PGLYRP2 (mAb AAA4), which were raised against 
human serum amidase. The 4 human PG recognition proteins (PGLYRPs) are pattern 
recognition molecules that are conserved throughout evolution. For many pathogenic 
and nonpathogenic Gram-positive and Gram-negative bacteria, human PG recogni-
tion proteins are bacteria killing and bacteria inhibiting.14,15 The immunohistochemistry 
methods for detection of intracellular PG have been previously described in detail.16,17 
In brief, frozen sections of 6 μm in thickness were fixed with freshly prepared acetone 
containing 0.02% of hydrogen peroxide to inhibit endogenous peroxidase activity for 
10 min. Histochemical revelation of endogenous peroxidase with 4-chloro-1-naphthol 
was done first. Next, the sections were incubated overnight with primary antibodies 
at previously determined optimal dilutions at 4 °C. Secondary enzyme-labelled anti-
bodies were applied and incubated at room temperature. Between incubations the 
slides were rinsed twice in phosphate-buffered saline/0.05% Tween 20. Histochemical 
revelation of alkaline phosphatase and horse radish peroxidase was done using Fast 
Blue BB base (blue reaction product; Sigma-Aldrich, St. Louis, MO, USA) and 3-amino 
9-ethyl carbazole (AEC, Sigma-Aldrich, St. Louis, MO, USA). Finally, sections were 
counterstained in haematoxylin and mounted in Kaiser’s glycerine gelatine with a 
cover slip. Sections of reactive human tonsils were used as internal positive control 
tissue. Staining controls were done by omission of the primary antibody and isotype-/
subclass-matched negative control antibodies. To determine whether presence of PG 
is related to macrophage infiltration, sections of 3 patients were additionally stained 
for the presence of macrophages by acid phosphatase enzyme histochemistry. All 
sections were evaluated by 2 independent observers blinded to the staining protocol 
and tissue donor identity.
results
Clinical data are presented in Table 1. Aerobic or facultative organisms were isolated 
in 3 patients, anaerobic bacteria in 3 patients, and mixed aerobic and anaerobic mi-
crobiota in 3 patients (Table 2). In 1 patient, the culture was negative. The organisms, 
cultured from granulation tissue in the fistula tract, were bowel derived, skin derived, 
or a combination of both. No mycobacterium species were grown from any of the 10 
patients. 16S rRNA sequencing used in the present study failed to identify bacteria in all 
but 1 patient (Table 2). In this patient, Escherichia coli was identified. Failure to detect 
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bacteria in the other 9 patients was most likely caused by low numbers of organisms. 
Therefore, the culture-positive results were considered to be clinically insignificant. In 
contrast, immunohistochemical analysis revealed bacterial PG-containing cells (Fig. 1) 
and a host response to PG reflected by PGLYRP expression in the majority of patients 
(Fig. 2 and Table 3). Bacterial PG-containing cells were detected in 90% of the pa-
tients. Antibody 2E9 detected PG in 5 patients, while antibody15704 raised against S. 
aureus PG identified PG in 9 patients. In 5 patients, both antibodies demonstrated the 
presence of PG. In all 3 patients with additional staining for macrophage infiltration, 
a high number of macrophages containing PG were shown (Fig. 3). In 6 patients, a 
host response to PG was detected by immunostaining with antibodies against PG 
recognition proteins, PGLYRP1 (188C424) and PGLYRP2 (mAb AAA4). PGLYRP1 was 
detected in 6 patients and PGLYRP2 in 2 patients. In 2 patients, both antibodies against 
PGLYRPs identified a host response. In 6 patients, binding of mAb for both bacterial 
Table 2. Conventional microbiology and 16S rRNA sequencing of fistula tissue
Subject Aerobic Anaerobic Mycobacteria
16S rRNA gene 
sequencing
1 Skinflora Negative Negative Negative
2 Negative E. coli Negative E. coli
3 Mixed flora Mixed flora Negative Negative
4 Pantoea spp Negative Negative Negative
5 Negative Negative Negative Negative
6 Hemolytic 
streptococcus 
group C
Mixed flora Negative Negative
7 CNS group 1 Mixed flora Negative Negative
8 Negative Mixed flora Negative Negative
9 S. aureus group 1 / 
Skinflora
Negative Negative Negative
10 Negative Peptostreptococcus 
asaccharolyticus group 1
Negative Negative
CNS = coagulase-negative staphylococcus.
Figure 1. Peptidoglycan is present in cells within infiltrates of the fistula tissue. Presence of peptidogly-
can (red) was detected by antibody 15704 directed against S. aureus PG. Magnifications are 10x, 20x, 
and 40x (from left to right).
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PG-containing cells and a host response to PG were identified. Of these 6 patients, 
1 showed binding of all antibodies. In 1 patient, none of the antibodies generated 
a signal. There were no obvious exceptional clinical parameters in these 2 patients. 
Figure 2. The host response to peptidoglycan is reflected by PGLYRP2 expression. PGLYRP2 (red) was 
detected by the antibody AAA4. Magnifications are 10x, 20x, and 40x (from left to right).
Table 3. Peptidoglycan and PGLYRPs in fistula tissue
Subject
Presence of peptidoglycan Host response to peptidoglycan
mAb 2E9 mAb 15704 PGLYRP1 PGLYRP2
1 – – – –
2 – + + +
3 – + + –
4 – + – –
5 + + + –
6 + + + –
7 + + + +
8 + + + –
9 – + – –
10 + + – –
+ = positive staining results; – = negative staining results.
Figure 3. Parts of PG-containing cells are macrophages. Infiltrating macrophages were demonstrated by 
enzyme histochemistry for acid phosphatase activity (bright red). PG was visualized in blue. An example 
of a double-positive cell is prominently present in the centre of the image. Infiltrates also contain abun-
dant numbers of cells containing PG but lacking acid phosphatase activity. These may include neutrophils 
and dendritic cells. Magnifications are 400x, 630x, and 1000x (from left to right).
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The outcome of surgery does not seem to be related to the results of conventional 
microbiology, 16S rRNA sequencing, or immunohistochemical analysis.
discussioN
This pilot study shows that, although the numbers of bacteria in high transsphincteric 
fistulas seem too low to contribute to the ongoing inflammation in the remaining 
fistula tract, pro-inflammatory peptidoglycan (PG) is readily detectable in the majority 
of the fistulas and hence may contribute to the ongoing inflammation. The organisms, 
cultured from granulation tissue obtained from the fistula tract, represented bowel-
derived, skin-derived, or a combination of both microbiota types. It seems unlikely 
that permanent infection with these species contributes to the chronicity of perianal 
fistulas, since they were present in such small numbers that 16S rRNA sequencing 
could not detect them. In contrast, Immunohistochemical analysis revealed bacterial 
PG-containing cells and a host response to PG in the majority of patients. It is gener-
ally accepted that perianal fistulas are secondary to perianal abscesses. After incision 
and drainage of such an abscess, a fistula remains in about half of the patients.18,19 It 
is not clear which factors contribute to the development of a chronic and persistent 
fistula. The microbiology of perianal abscesses has been well described.19-21 The bac-
teria cultured from perianal abscesses include bowel-derived organisms, skin-derived-
organisms, or a combination of both. According to some authors, bowel-derived 
organisms are associated with subsequent occurrence of a fistula.19,20 However, this 
finding could not be confirmed by others.22 Three studies have been conducted to as-
sess the microbiology of cryptoglandular perianal fistulas.6-8 Seow-Choen et al.8 were 
the first to show that the microbiota in perianal fistulas is similar to the microbiota of 
perianal abscesses. However, cultures of granulation tissue, obtained from perianal 
fistulas, yielded much smaller numbers of organisms in comparison with pus obtained 
from perianal abscesses. Furthermore, they were not able to detect pathogenic or-
ganisms. Similar findings have been reported by others.6,7 The conventional culture 
techniques used in these studies have several drawbacks. First, they require rapid and 
accurate handling of the material to prevent bacterial death. Second, conventional 
culture techniques are largely dependent on the type and range of media used. Third, 
the majority of bacteria are not able to thrive in isolation.23 Particularly, the isola-
tion of anaerobic bacteria is problematic.24 In the present study, conventional culture 
techniques as well as 16S rRNA gene sequencing were used. PCR has been developed 
to aid in the diagnosis of bacterial infection by detecting bacterial genetic material.10,25 
Unlike culture, most molecular assays are designed specifically for a single microbial 
species. This provides high sensitivity and specificity. However, multiple assays may be 
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required to screen for multiple organisms. Broad-range assays, based on ribosomal 
genes (rDNA), are designed to overcome this limitation. Bacterial rRNA contains motifs 
of highly conserved nucleotide sequences that are shared by all bacterial species, 
interspersed with variable regions that are genus- or species specific. The DNA se-
quences of the variable regions form the basis of the phylogenetic classification of 
microbes.26 By using PCR primers that are targeted at conserved regions of rDNA, it 
is possible to design broad-range PCRs capable of detecting DNA from almost any 
bacterial species. Bacterial identification is based on nucleotide sequencing of the PCR 
product followed by comparison of this sequence with known sequences in GenBank 
or other databases.27,28 In the present study, 16S rRNA gene sequencing failed to 
identify bacteria in all but 1 patient. This was most likely caused by a very low number 
of organisms. Therefore, it seems unlikely that the bacteria, cultured from granulation 
tissue, obtained from perianal fistulas contribute to the chronicity of these fistulas. To 
the author’s knowledge, the present study is the first to describe PG in perianal fistulas. 
PG is a major component of the bacterial cell wall with muramyl dipeptide as the main 
degradation product. Both PG and muramyl dipeptide have potent pro-inflammatory 
properties. PG induces inflammasome NLRP3-mediated caspase-1 (interleukin-1β 
convertase) activation and thereby processing and secretion of the pro-inflammatory 
cytokine interleukin-1β.29,30 The highly potent ‘fever cytokine’ interleukin-1β is able 
to stimulate the expression of pro-inflammatory genes and acts on various organs. 
Pro-inflammatory cytokines interleukin-1β and interleukin-8 (a neutrophil chemoat-
tractant) are expressed in biopsies of perianal fistulas.31 Interleukin-8 was strongly 
expressed in the biopsies taken from the proximal part of the fistula tract. Moreover, 
interleukin-1β was strongly expressed in the biopsies taken from the distal part of 
the fistula tract. This could be relevant to our finding of bacterial PG-containing cells 
and a host response to PG in the distal part of the fistula tract. This suggests that PG 
may stimulate the secretion of interleukin-1β in perianal fistulas and might play an 
essential role in the ongoing inflammation in perianal fistulas. The outcome of surgery 
does not seem to be related to the results of conventional microbiology, 16S rRNA 
sequencing, or immunohistochemical analysis. As this is a pilot study, the number of 
patients is small. We are aware of this limitation and we are currently preparing a 
larger study on the presence of PG in different parts of perianal fistulas. This would 
also allow to further pursue questions on the identity of phagocyte subsets containing 
PG in addition to macrophages, such as dendritic cells and neutrophils, and on the 
direct relations between PG presence and local production of inflammatory mediators 
including interleukin-1.
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conclusion
This pilot study demonstrates a paucity of bacteria in the fistula tract. Therefore, it 
seems unlikely that bacterial infection plays a major role in maintaining the fistulous 
disease. In contrast, we detected pro-inflammatory PG and a host response to PG in 
the majority of patients. We suggest that PG stimulates the secretion of interleukin-1β 
and other inflammatory mediators in perianal fistulas and might play an essential role 
in the ongoing inflammation.
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AbstrAct
background
Sphincter preserving procedures for the treatment of transsphincteric fistulae fail in 
one out of every three patients. It has been suggested that failure is due to ongoing 
disease in the remaining fistula tract. Cytokines play an important role in inflamma-
tion. At present biologicals targeting cytokines are available. Therefore, detection and 
identification of cytokines in anal fistulae might have implications for future treatment 
modalities. The objective of the present study was to assess local production of a 
selected panel of cytokines in anal fistulae, including pro-inflammatory interleukin 
(IL)-1β and tumor necrosis factor α (TNF-α).
method
Fistula tract tissue was obtained from 27 patients with a transsphincteric fistula of 
cryptoglandular origin who underwent flap repair, ligation of the intersphincteric 
fistula tract (LIFT), or a combination of both procedures. Patients with a rectovaginal 
fistula or a fistula due to Crohn’s disease were excluded. Frozen tissue samples were 
sectioned and stained using advanced immuno-enzyme staining methods for detec-
tion of selected cytokines, IL-1β, IL-8, IL-10, IL-12p40, IL-17A, IL-18, IL-36 and TNF-α. 
Presence and frequencies of cytokine-producing cells in samples were quantitated.
results
The key finding was abundant expression of IL-1β in 93% of the anal fistulae. Fre-
quencies of IL-1β producing cells were highest (>50 positive stained cells) in 7% of 
the anal fistulae. Also, cytokines IL-8, IL-12p40 and TNF-α were present in respectively 
70%, 33% and 30% of the anal fistulae.
conclusion
IL-1β is expressed in the large majority of cryptoglandular anal fistulae, as well as 
several other pro-inflammatory cytokines.
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iNtroductioN
In a previous study, conducted in patients with a persistent anal fistula after flap 
repair, we observed complete healing of the flap, except at the site of the original 
internal fistula opening.1 This observation and absence of factors predisposing to 
failure suggest that persistence of anal fistulae is caused by ongoing inflammation 
in the remaining fistula tract. A recent study, conducted at our institution, revealed 
that the majority of anal fistulae are lined with granulation tissue (75%), which is 
suggestive of an inflammatory response.2 Since local bacterial replication might be 
an inflammatory factor we performed another study.3 A paucity of bacteria was 
observed in the fistula tracts. Bacterial species were bowel derived, skin derived, or a 
combination of both. No mycobacterium species were identified. Therefore, it seems 
unlikely that bacterial infection plays a major role in persistence of fistula after surgery. 
These results were recently confirmed by Tozer et al..4 In the same study we detected 
pro-inflammatory peptidoglycan in the majority of anal fistulae.3 Peptidoglycan is a 
major component of the bacterial cell wall of both Gram positive and Gram negative 
species, providing structural strength and allowing bacteria to resist osmotic pressure. 
Peptidoglycan has potent pro-inflammatory properties and stimulates processing and 
secretion of the cytokine IL-1β.5-6 This suggests that even in the absence of local 
bacterial replication, bacterial components promote chronic inflammation. Studies on 
the pathogenesis of different chronic inflammatory diseases, such as Crohn’s disease, 
show that peptidoglycan is a powerful effector stimulating inflammation.7,8 Cytokines 
play an important role in inflammation. TNF-α, IL-1β and other cytokines promote 
inflammatory responses that cause many of the clinical problems associated with 
immune-mediated diseases, such as rheumatoid arthritis, hidradenitis suppurativa, 
ulcerative colitis and Crohn’s disease.9-12 Biologicals targeting cytokines, such as anti-
TNF-α and IL-1 receptor antagonist, are used in various diseases and clinical trials.13 
An overview of these agents is presented in Table 1, focusing on cytokines addressed 
in the current study. The question is whether one of these agents might play a role as 
adjunct in the treatment of anal fistulae. The objective of the present observational 
study was to detect and to identify cytokines in anal fistulae of cryptoglandular origin.
method
study design
Anal fistula tissue was obtained from 27 patients with a transsphincteric fistula of 
cryptoglandular origin that underwent transanal advancement flap repair (TAFR), liga-
tion of the intersphincteric fistula tract (LIFT) or a combination of both procedures 
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Table 1. A summary of cytokines assessed and therapeutic options
Cytokine Main functions
Therapeutic molecules
(generic name of 
biological*)
Main (potential) 
clinical 
applications
IL-1β Inflammatory response to infection. 
Mediates fever and promotes formation of 
acute phase proteins by the liver. Activation 
of T and B lymphocytes. Elevates adhesion 
molecules on endothelium. Induces other 
cytokines such as IL-6. Resembles TNF-α in 
its inflammatory properties.
Anakinra (IL-1 receptor 
antagonist);
Rilonacept (IL-1 receptor 
fusion protein);
Canakinumab (anti-IL-β 
mab)
RA, CAPS such 
as Muckle Wells 
syndrome (MWS) 
and familial cold 
auto-inflammatory 
syndrome (FCAIS)
IL-8
alias 
CXCL8
Mediator of innate immune responses. 
Induces chemotaxis of T cells and 
neutrophilic granulocytes. Promotes 
phagocytosis and angiogenesis.
Limited Spectrum of (auto)-
inflammatory 
diseases
IL-10 Anti-inflammatory. Inhibits production 
of cytokines by many cell types. Inhibits 
activation and effector functions of T cells, 
monocytes and macrophages.
Limited, e.g. Tenovil 
(recombinant IL-10)
Spectrum of (auto)-
inflammatory 
diseases
IL-12p40 Differentiation of naive T cells into T-helper 
1 cells. Induction of IFN-γ in NK cells and 
T cells. Growth factor for activated CD4+ 
and CD8+ T lymphocytes and NK cells, and 
enhancement of their function.
Ustekinumab (mab against 
shared p40 subunit of IL-12 
and IL-23);
Briakinumab ( mab against 
shared p40 subunit of IL-12 
and IL-23)
Psoriasis, CD
IL-17A Central to induction and maintenance of 
proinflammatory responses. Induces other 
inflammatory cytokines and mediators, 
notably chemoattractants including those 
for neutrophilic granulocytes. IL-17A is 
critical to function of the Th17 subset of 
CD4+ lymphocytes.
Secukinumab (mab against 
IL-17A);
Ixekizumab (mab against 
IL-17A)
Brodalumab (mab against 
IL-17 receptor)
Psoriasis, RA, AS, 
RRMS
IL-18
(IL-1 
family)
Induces cell-mediated immunity to 
intracellular pathogens. Induces IFN-γ, and 
other cytokines and chemokines.
Limited Spectrum of (auto)-
inflammatory 
diseases
IL-36
(IL-1 
family)
Acts directly on naive T cells, enhancing 
proliferation and IL-2 production. Stimulates 
Th1 responses. Acts on dendritic cells. 
Appears to be especially expressed and 
functional in the skin.
Limited Spectrum of (auto)-
inflammatory 
diseases
TNF-α Participates in inflammation, wound healing, 
and remodelling of tissue. Induces apoptosis, 
other cytokines and inflammation. Facilitates 
leukocyte recruitment, induces angiogenesis, 
and promotes fibroblast proliferation. 
Induces expression of adhesion molecules on 
vascular endothelium.
Infliximab (anti-TNF mab);
Adalimumab (anti-TNF mab);
Golimumab (anti-TNF mab);
Etanercept (soluble receptor 
for TNF)
Certolizumab (anti-TNF mab)
RA, CD, UC, AS, 
PsA, JIA, Psoriasis, 
HS
*Nomenclature of biologicals includes, -cept for receptor, -ki(n) for interleukin -mab for monoclonal 
antibody, -ra for receptor antagonist, , -u for human, -zu for humanized. Abbreviations: AS, ankylosing 
spondylitis; CAPS, cyropyrin-associated periodic syndromes; CD, Crohn’s disease; HS, hidradenitis sup-
purativa. IL, interleukin; JIA, juvenile idiopathic arthritis; mab, monoclonal antibody; NK, natural killer; 
PsA, psoriatic arthritis; RA, rheumatoid arthritis; RRMS, relapsing remitting multiple sclerosis; TNF, tumor 
necrosis factor; UC, ulcerative colitis.14-17
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at the Division of Colon and Rectal Surgery, Erasmus MC, University Medical Center. 
Prior to the procedure patients underwent endoanal magnetic resonance imaging to 
visualize the course of the fistula tract and to determine the presence and location 
of associated abscesses. Patients with a rectovaginal fistula and/or a fistula due to 
Crohn’s disease were excluded from this study. None of the patients had hepatitis B 
and/or HIV at the time of surgery. None of the patients used metronidazole and/or 
antibiotics prior to surgery. Baseline patient and fistula characteristics are presented 
in Table 2. All patients provided informed consent meeting the standards set by the 
hospital’s Institutional Review Board. All operations were performed by one surgeon 
and several colorectal surgery fellows. Patients were treated in a day-care setting.
operative techniques
We described our techniques of TAFR and LIFT earlier in detail.18
sample collection
The external fistula opening was enlarged and the fistula tract was excised as far 
as possible until the outer border of the external anal sphincter. Immediately after 
excision the fistula tract was frozen using dry ice and transported to the laboratory 
Table 2. Baseline patient and fistula characteristics (n = 27)
Patient and/or fistula characteristic N
Age at surgery (years) 46.2 ± 10.5
Sex (male) 15 (55.6)
Fistula type
HTS 22 (81.5)
LTS 5 (18.5)
Location internal fistula opening*
Anterior 10 (37.0)
Posterior 15 (55.6)
Lateral 1 (3.7)
Location external fistula opening
Anterior 0 (0)
Posterior 4 (14.8)
Lateral 23 (85.2)
Type of operative technique
TAFR 13 (48.2)
LIFT 6 (22.2)
TAFR & LIFT 8 (29.6)
Categorical variables are presented as numbers (%). Continuous values are expressed as mean ± SD. 
Abbreviations: HTS, high transsphincteric fistula; LTS, low transsphincteric fistula; TAFR, transanal ad-
vancement flap repair; LIFT, ligation of intersphincteric fistula tract. *The internal fistula opening was not 
identified in one patient.
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for cryopreservation. Excised tissue was cryopreserved in liquid nitrogen and subse-
quently stored at -80 ˚C for processing. The value of samples from healthy controls 
or patients with other afflictions as reference groups has been considered. However, 
the only possibility to obtain healthy anal tissue (including anal glands) from patients 
is during major surgery of this specific part of the body. Indications for these types of 
surgery are Crohn’s disease or colorectal cancer. These diseases would certainly bias 
any findings as they are associated with increased expression of cytokines.11,19 Also 
the potential value of samples from deceased patients without colorectal diseases as 
reference groups has been considered. However, we reasoned that any cause of death 
and death itself might probably bias any findings. Therefore, we have decided to use 
no reference group.
in situ analysis of cytokine-producing cells
Frozen tissue samples were sectioned and stained using advanced immuno-enzyme 
staining methods for detection of selected cytokines IL-1β, IL-8, IL-10, IL-12p40, 
IL-17A, IL-18, IL-36 and TNF-α. This selection of cytokines was designed based on 
current concepts of tissue inflammation versus inflammation control (e.g. IL-10), and 
the availability of clinically approved biologicals (see Table 1). In short, frozen sections 
of 6 μm in thickness were dried overnight in a humidified box before getting fixed 
with freshly prepared acetone containing 0.02% of hydrogen peroxide to inhibit en-
dogenous peroxidase activity by cells in the tissue (e.g. granulocytes) for 10 minutes. 
Histochemical revelation of endogenous peroxidase with 4-chloro-1-naphthol was 
performed resulting in a dense blue-black precipitate. After this the sections were in-
cubated overnight with primary antibodies at previously determined optimal dilutions 
at 4 °C. Respectively, the following commercially available antibodies were used anti-
human IL-1β (clone 8516.31, R&D Systems, Minneapolis, MN), anti-human IL-8 (clone 
G265-8, BD Biosciences Pharmingen, San Jose, CA), anti-human IL-10 (clone JES3-
12G8, BD Biosciences Pharmingen), anti-human IL-12p40 (clone C8.6, BD Biosciences 
Pharmingen), anti-human IL-17A (clone e B 1064 CAP, eBioscience, Inc., San Diego, 
CA), anti-human IL-18 (rabbit IgG, Thermo Scientific, Rockford, IL), anti-human IL-36 
(clone 3A12, Abcam, Cambridge, MA) and anti-human TNF-α (clone 61E7, U-CyTech 
Biosciences, Utrecht, the Netherlands). Secondary enzyme-labelled antibodies were 
applied and incubated at room temperature. Between incubations the slides were 
rinsed twice in phosphate-buffered saline/0.05% Tween 20. Histochemical revelation 
of horseradish peroxidase activity was performed using amino ethyl carbazole (AEC, 
Sigma-Aldrich, St. Louis, MO) for a bright red translucent staining. Finally, sections 
were counterstained with haematoxylin and mounted in Kaiser’s glycerine gelatine 
with a cover slip. Sections of reactive human tonsils were used as internal positive con-
trol tissue since they contain numerous leukocytes producing a variety of cytokines. 
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Staining controls were done by omission of the primary antibody and by isotype-and 
subclass-matched negative control antibodies.
Quantitation of cytokine-producing cells
In order to interpret the presence and frequencies of cytokine-producing cells, the 
number of positive stained cells in the fistula samples were scored from zero to four. 
Respectively, zero for no stained cells, one for 1 to 5 stained cells, two for 6 to 20 
stained cells, three for 21 to 50 stained cells and four for >50 stained cells. All sections 
were evaluated by two independent observers.
statistical analysis
Continuous data are presented as mean values with standard deviation. Categorical 
data are presented as frequencies or percentages. Data were analysed by use of SPSS-
IBM® software version 20.0 for Windows® (SPSS, Chicago, IL).
results
Anal fistula samples were obtained from 27 patients with a transsphincteric fistula 
of cryptoglandular origin during surgery. Of these, 13 patients (48%) underwent 
flap repair, 6 patients (22%) underwent ligation of the intersphincteric fistula tract 
(LIFT) and 8 patients (30%) underwent a combination of both procedures. Baseline 
patient and fistula characteristics are presented in Table 2. Presence and frequencies 
of cytokine-producing cells in anal fistula samples were evaluated using a pathology 
scoring system. These findings are presented in Table 3. In the positive control tissue, 
reactive human tonsils from children, cells producing all cytokines were detected in 
Table 3. Presence and frequencies of cytokine-producing cells in anal fistulae (n=27)
Cytokine N (%)
No stained 
cells
1 to 5 
stained 
cells
6 to 20 
stained cells
21 to 50 
stained cells
>50 stained 
cells
IL-1β 25 (92.6) 2 (7.4) 4 (14.8) 12 (44.4) 7 (26.0) 2 (7.4)
IL-8 19 (70.4) 8 (29.7) 4 (14.8) 6 (22.2) 5 (18.5) 4 (14.8)
IL-10 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-12p40 9 (33.3) 18 (66.7) 1 (3.7) 7 (25.9) 1 (3.7) 0 (0)
IL-17A 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-18 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IL-36 0 (0) 27 (100) 0 (0) 0 (0) 0 (0) 0 (0)
TNF-α 8 (29.6) 19 (70.4) 3 (11.1) 4 (14.8) 1 (3.7) 0 (0)
Variables are presented as numbers (%). Abbreviations: IL, interleukin; TNF, tumor necrosis factor.
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varying numbers, as predicted. This confirms the anticipated reactivity of the anti-
bodies used and their suitability for detection of cytokines in frozen tissue. In 93% 
of the fistula samples the prominent pro-inflammatory cytokine IL-1β was present. 
Frequencies of IL-1β producing cells were highest (>50 positive stained cells) in 7% 
of the fistula samples (Fig 1). The cytokines IL-8, IL-12p40 and TNF-α were present in 
respectively 70%, 33% and 30% of the fistula samples (Fig 1). IL-10, IL-17A, IL-18 
and IL-36 could not be detected.
discussioN
The key finding of the present study was the abundant expression of pro-inflammatory 
cytokine IL-1β in 93% of the anal fistulae. Also, the cytokines IL-8, IL-12p40 and 
TNF-α were expressed in a high number of anal fistulae (Table 3). Limitations of this 
study are the lack of a control or reference group and a potential selection bias caused 
Figure 1. IL-1β and IL-8 in anal fistula samples
IL-1β and IL-8 are expressed by cells within infiltrates of the anal fistula tissue. Presence of IL-1β (red) and 
IL-8 (red) was detected by specific antibodies. IL-1β is presented in the two upper images and magnifica-
tions are 100x and 200x (from left to right). IL-8 is presented in the two lower images and magnifications 
are 100x and 400x (from left to right).
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by the status of our institution as tertiary referral center. Strengths of the study are 
the large number of patients, the comprehensive panel of cytokines studied, and 
the homogeneity of the patient group. IL-1 is a central mediator of innate immunity, 
inflammation and fever. As a highly active pro-inflammatory cytokine it contributes to 
lowering pain thresholds and to tissue damage. IL-1β can be produced by many differ-
ent cell types, with a prominent role of monocytes and macrophages.20 The stimulus 
can be microbial products, cytokines and even IL-1β itself.21 Self-induction by IL-1 is 
part of the mechanism of auto-inflammation.12 The IL-1β precursor is inactive within 
the cell and biologically active IL-1β is produced by inflammasomes that cleave pro-IL-
1β using caspase-1. Based on our previous study, it seems likely that peptidoglycan is 
a one of the potential stimuli for the expression of IL-1β in anal fistulae. Peptidoglycan 
induces inflammasome NLRP3-mediated caspase-1 activation and thereby processing 
and secretion of IL-1β. This concept is supported by presence of peptidoglycan in 
90% of cryptoglandular anal fistulae.3 Self-induction by IL-1 may also be involved. 
Overall, our findings suggest that cytokines contribute to the inflammatory process 
in cryptoglandular anal fistulae. Flap repair has been advocated as the treatment of 
choice for high transsphincteric anal fistulae and enables healing in two of every three 
patients.22,23 A pilot study by Verhagen et al. showed that flap repair with additional 
injection of platelet-rich plasma (PRP) in the anal fistula tract increases the healing 
rate to 90%.24 A second study with a longer duration of follow-up confirmed these 
promising results.25 According to the authors PRP improves wound healing and may 
therefore improve the closure rate of anal fistulae. PRP has also anti-inflammatory 
potentials. Kim et al. showed that PRP is able to suppress expression of degrading 
enzymes and mediators induced by TNF-α and IL-1β.26 It seems likely that this mode of 
action also contributes to the higher healing rate after flap repair. Currently, three IL-1 
antagonists (Anakinra, Rilonacept, and Canakinumab) targeting IL-1β are approved 
for treatment of various diseases (Table 1). Studies on IL-1 antagonists targeting a 
broad spectrum of new indications, such as hidradenitis suppurativa, show promising 
results.27 In conclusion, pro-inflammatory IL-1β is expressed in the large majority of 
cryptoglandular anal fistulae and we propose that adjunct treatment of anal fistulae 
by targeting cytokines may potentially be beneficial. Further research on this matter 
is mandatory.
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Anal fistulas have been treated since the beginning of medicine and the classical treat-
ment of anal fistulas is to surgically lay-open the fistula (fistulotomy). Although this 
treatment is highly effective for healing of anal fistulas, fistulotomy risks diminished 
fecal continence in patients with anal fistulas that require division of a large proportion 
of the anal sphincters. In modern colorectal surgery the main objective in treatment 
of anal fistulas is healing of the fistula without diminished fecal continence. Recent 
findings even indicate that for most patients it is more important to minimize their 
risk of diminished faecal continence than to have a highly successful treatment for 
their fistula.1 Over time several sphincter preserving procedure have been developed 
for anal fistulas, such as transanal advancement flap repair (TAFR) and ligation of the 
intersphincteric fistula tract (LIFT). Although these sphincter preserving procedures are 
effective in preventing diminished fecal continence after surgery, they seem less ef-
fective for healing of anal fistulas than fistulotomy. The healing rate after TAFR varies 
between 60 and 70% and the healing rate after LIFT varies between 50 and 70%.2-11 
The reason for these rather disappointing results remains unclear and predictors of 
outcome have not been defined.
In this thesis, we first evaluated several sphincter preserving procedures for anal 
fistulas and factors that might affect the outcome of treatment. Anal fistulas have 
always been considered a surgical challenge and most studies have been conducted to 
optimize surgical treatment by evaluating and developing new techniques. However, 
healing rates remained disappointing and it seemed unlikely that surgical treatment 
will ever lead to fistula healing in all patients. This made us change our approach. We 
suggested that ongoing inflammation might play an important role in anal fistulas and 
potentially in their persistence after surgery. Studies on etiology and pathogenesis of 
anal fistulas are rare, but we suggested that a better understanding of the disease 
will eventually help in the development of new treatments of anal fistulas. Therefore, 
in the second part of this thesis, we aimed to gain a better understanding of the 
pathogenesis of anal fistulas.
treAtmeNt
Classification of anal fistulas is based on the course of the fistula tract in relation to 
the anal sphincters.12 Of the four main types of fistulas, the transsphincteric fistula is 
the second most common one. Transsphincteric fistulas are classified as high or low. 
For many surgeons this classification is useful for selecting the optimal treatment 
and supporting the choice between non-sphincter preserving procedures, such as 
fistulotomy, and sphincter preserving techniques, such as TAFR and LIFT. Although 
the distinction between high and low transsphincteric fistulas is commonly practiced, 
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it is unknown whether these fistulas have similar characteristics or not. In Chapter 2 
differences between high and low transsphincteric fistulas were evaluated. The study 
showed that low transsphincteric fistulas occurred more frequently at a younger age 
(42 vs. 47 years) and more often in females (43% vs. 30% in high transsphincteric 
fistulas). These fistulas were predominantly anterior (76% vs. 18% in high trans-
sphincteric fistulas) and were rarely associated with an abscess (4% vs. 54% in high 
transsphincteric fistulas). The internal opening of high transsphincteric fistulas was 
predominantly located in the posterior midline. Differences in location of internal 
fistula opening and gender are difficult to explain as there is no gender-specific distri-
bution of anal glands.13 However, we suggest that some of the low transsphincteric 
fistulas observed in females may be secondary to episiotomy and this may explain 
the difference in gender and age. The result of this study may have implications for 
clinical practice. In patients with a low transsphincteric fistula, fistulotomy is still 
advocated as the treatment of choice with a minimal risk of incontinence. There is 
growing evidence, however, that fecal continence is yet at risk following division of 
the lower third of the external anal sphincter, especially in females with an anterior 
fistula.14,15 Female patients are probably at risk because they have a shorter external 
anal sphincter, which is prone to damage during childbirth.16,17 In the study described 
in Chapter 2 almost half the patients with a low transsphincteric fistula were female. 
In these patients sphincter preserving techniques such as LIFT may be preferable to 
conventional fistulotomy.
Fistulotomy is not suitable for patients with a high transsphincteric fistula and 
TAFR has been advocated as the treatment of choice for these anal fistulas. Initially, 
reported healing rates after TAFR varied between 84% and 100%.18-21 However, it 
has become clear that TAFR fails in one of every three patients.2-6 It has been reported 
that smoking, obesity and previous attempts at repair adversely affect the outcome 
of TAFR.4,6,22,23 Because these findings could not be confirmed by other studies, it 
is still unclear whether these and other factors have an impact on the outcome of 
TAFR.4,5,23-25 In Chapter 3 seventeen potential predictors of outcome were assessed 
in 252 patients with a high transsphincteric fistula who underwent TAFR. The study 
showed that the outcome after TAFR is significantly better in patients with horseshoe 
extension. An explanation for this unexpected finding might be the possibility that 
the course of the fistula depends on the severity of the fistulous disease. The more 
fulminant the fistulous disease, the more perpendicular the fistula might traverse 
through the anal sphincters, resulting in a direct course to the external fistula opening.
In a previous study performed at our institution, the outcome of repeat TAFR was 
examined in 26 patients, who experienced a failure after the initial procedure. In all of 
these patients complete healing of the flap was noticed, except at the site of the origi-
nal internal opening.26 This remarkable clinical finding raised the question whether 
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ongoing disease in the remaining tract contributes to persistence of the fistula after 
flap repair. Most of the remaining tract is located in the intersphincteric plane near the 
origin of the fistula. LIFT was introduced as an attractive sphincter-preserving alterna-
tive by Rojanasakul and he observed 94% primary fistula healing.27 Based on these 
promising results, we suggested that this procedure could be useful for eradication of 
the ongoing disease in the remaining fistula tract, thereby improving the outcome of 
TAFR. In Chapter 4 the effect of an additional LIFT on the outcome of TAFR in patients 
with a high transsphincteric fistula was evaluated. Primary healing was observed in 
51%. Of the 49% with a failure, the original transsphincteric fistula persisted in 29%. 
In 20%, the transsphincteric fistula was converted into an intersphincteric fistula. 
These patients underwent subsequent fistulectomy, which was successful in all of 
them. The overall healing rate was 71%. In conclusion, an additional LIFT does not 
improve the outcome of TAFR.
Fistulotomy is considered the treatment of choice for patients with a low trans-
sphincteric fistula. However, there is growing evidence that the risk of diminished 
fecal continence following fistulotomy is significant, especially in female patients with 
an anterior fistula and patients with diminished anal sphincter function.14,15 LIFT is 
a sphincter preserving procedure that may also be applied in low transsphincteric 
fistulas. In Chapter 5 the clinical results of LIFT in patients with a low transsphincteric 
fistula were described. Primary healing was observed in 82%. In patients without 
primary healing, the transsphincteric fistula was converted into an intersphincteric 
fistula. This phenomenon suggests that LIFT is sufficient on the side of the external 
anal sphincter but not always on the side of the internal anal sphincter, resulting in 
ongoing inflammation in the intersphincteric plane. In Chapter 7 we revealed that the 
intersphincteric fistula tract of most anal fistulas is lined with granulation tissue. The 
presence of granulation tissue may be suggestive of an inflammatory process. Conver-
sion to an intersphincteric fistula due to ongoing intersphincteric disease requires a 
second procedure, fistulotomy, including division of the lower part of the internal 
anal sphincter. This could be considered a disadvantage of the LIFT technique, with 
a potential risk of continence disturbance. Other studies have reported diminished 
fecal continence in up to 38% of the patients that underwent fistulotomy for an 
intersphincteric fistula. In this study the median Rockwood Fecal Incontinence Sever-
ity Index (RFISI) was not changed. We suggest that LIFT is a good alternative for 
fistulotomy. However, in some patients a second procedure is needed.
In Chapter 6, we evaluated TAFR combined with drainage of associated abscesses 
in high intersphincteric fistulas in a series of 14 patients. Intersphincteric fistulas with 
a high upward extension, up to or above the level of the puborectal muscle, in the 
intersphincteric plane are rare.12 Most of these fistulas have no external opening and 
they are frequently associated with a high intersphincteric and/or supralevator abscess. 
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Division of a large amount of internal anal sphincter by extended fistulotomy has a 
potential risk of diminished fecal continence. To our knowledge no reports are avail-
able regarding sphincter preserving alternatives for the treatment of these fistulas. 
In this study TAFR with adequate drainage of the abscesses was successful in 79%, 
except in patients with supralevator extension. In these patients additional procedures 
(including adequate drainage with or without TAFR) were needed to achieve healing. 
Since preoperative endoanal MRI revealed associated abscesses in 13 patients, we 
advise appropriate preoperative imaging for all high intersphincteric fistulas. This pro-
vides essential information and guides the surgical procedure, especially regarding the 
approach of associated abscesses and the identification of intersphincteric horseshoe 
extension.
PAthoGeNesis
Epithelialization is considered a major cause for persistence of anal fistulas. Lunniss et 
al. observed epithelium lining in the majority of anal fistulas and van Koperen et al. 
observed epithelium lining predominantly near the internal fistula opening. Although 
the effect of this epithelialization on fistula healing was not assessed, both studies 
stated that this might be a cause for the persistence of the fistula.28,29 In Chapter 7, 
we assessed the prevalence of epithelialization of the fistula tract and its effect on the 
outcome of fistula surgery. We observed epithelialization in only 25% and granulation 
tissue in 75% of the fistula tracts. There was no difference in outcome between 
fistulas with or without epithelialization. It has been suggested that perpetuation of 
inflammation prevents the migration and arrangement of myofibroblasts, which are 
the key cells in the tissue repair process.30 These cells are able to form a new basement 
membrane, which is a prerequisite for the migration of epithelial cells. The lack of 
epithelialization and presence of granulation tissue in the majority of the fistula tracts 
may be an expression of ongoing inflammatory process.
Some authors studied the bacteriology of anal fistulas.31-33 Their reports failed to 
demonstrate pathogenic bacteria. Moreover, only low numbers of organisms were 
found, suggesting that permanent infection is not a major contributing factor to the 
persistence of perianal fistulas. Since these data were obtained only with the use of 
conventional microbiological culture techniques and live bacteria as well as inflam-
matory bacterial remnants could potentially contribute to the ongoing inflammation 
in the remaining fistula tract, we assessed bacteria in the fistula tract by means of 
conventional microbiological culture and 16S rRNA gene sequencing, and we assessed 
pro-inflammatory bacterial peptidoglycan (PG) by immunohistochemistry in Chapter 
8. Studies on the pathogenesis of different chronic inflammatory diseases, such as 
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Crohn’s disease, show that PG is a powerful effector stimulating inflammation.34,35 
A paucity of bacteria was observed in the fistula tracts. Bacterial species were bowel 
derived, skin derived, or a combination of both. Therefore, it seems unlikely that bac-
terial infection plays a major role in persistence of fistula after surgery. These results 
were recently confirmed by Tozer et al.36 In contrast, we detected pro-inflammatory 
PG in the majority of anal fistulas. PG has potent pro-inflammatory properties and 
stimulates processing and secretion of the cytokine interleukin (IL)-1β. This suggests 
that even in the absence of local bacterial replication, bacterial components promote 
chronic inflammation.
Cytokines, such as IL-1β, play an important role in inflammation. At present, many 
biologicals targeting cytokines or their receptors are available for treatment of a wide 
array of inflammatory diseases. Therefore, detection and identification of cytokines 
in anal fistulas might have implications for future treatment modalities. We assessed 
the local production of a selected panel of cytokines in anal fistulas, including pro-
inflammatory IL-1β and tumor necrosis factor α (TNF-α). The result are described in 
Chapter 9. The key finding of this study was the abundant expression of IL-1β in 93% 
of the anal fistulas. Also, cytokines IL-8, IL-12p40 and TNF-α were present in respec-
tively 70%, 33% and 30% of the anal fistulas. We propose that adjunct treatment of 
anal fistulas by targeting cytokines may potentially be beneficial. Further research on 
this matter is warranted.
future PersPectives
The objective of modern anal fistula treatment is healing of the fistula without di-
minished fecal continence. Sphincter saving techniques have been developed for anal 
fistulas, for which fistulotomy is not suitable. Treatment of these anal fistulas remains 
challenging and to some extent disappointing. Despite our effort it seems unlikely that 
surgical treatment alone will ever lead to fistula healing in all patients. We suggest 
that inflammation plays a role. In Chapter 9, we observed the abundant expression 
of pro-inflammatory cytokine IL-1β in the majority of anal fistulas. Cytokines play an 
important role in inflammation and elevated levels of IL-1β are observed in diseases, 
such as hidradenitis suppurativa. Currently, three IL-1 antagonists targeting IL-1β are 
approved for treatment of various diseases and new indications are on their way. 
Treatment of anal fistulas may need a new approach, combining surgery with treat-
ment of inflammation. Proposals for future research and treatment:
- Research on random treatment options for anal fistulas should stop. We first have 
to understand the disease before we can treat it.
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- Future research should focus on etiology and pathogenesis of anal fistulas. This is 
highly underrated in the current literature. Furthermore, this may provide targets 
for additional treatment.
- Sphincter preserving procedures alone do not enable the healing of all anal fis-
tulas. It seems likely that these procedures should be combined with additional 
treatment of inflammation within the fistula tract to improve the outcome. Further 
studies on this matter are necessary.
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Anale fistels worden behandeld sinds het begin van de geneeskunde. De klassieke 
behandeling van anale fistels is de fistel chirurgisch open te leggen (fistulotomie). 
Hoewel dit een erg effectieve behandeling is, bestaat er een risico op verminderde 
fecale continentie bij patiënten met een anale fistel die hoog door de anale kringspie-
ren loopt.
In de moderne colorectale chirurgie is behalve genezing ook behoudt van fecale 
continentie belangrijk. Recent onderzoek toont namelijk dat voor de meeste patiënten 
een laag risico op fecale incontinentie belangrijker is dan hoge kans op genezing. 
Over de tijd zijn er verscheidenen kringspier sparende operaties ontwikkeld voor 
anale fistels, zoals de transanale mucosa verschuivingsplastiek (TAMVP) en ligatie van 
het intersfincterische fistel traject (LIFT). Hoewel deze kringspier sparende operaties 
effectief zijn in het voorkomen van verminderde fecale continentie na de operatie, 
leiden ze minder vaak tot genezing dan een fistulotomie. De genezing na een TAMVP 
varieert tussen 60 en 70% en het genezingspercentage na een LIFT varieert tussen 50 
en 70%. De reden voor deze teleurstellende resultaten is onduidelijk en voorspellers 
voor de uitkomst van de operaties zijn tot op heden niet duidelijk geïdentificeerd.
In het proefschrift hebben we eerst de toepassing van verschillende kringspier spa-
rende operaties onderzocht en geprobeerd voorspellers voor de uitkomst van de ope-
raties te identificeren. Anale fistels worden namelijk beschouwd als een chirurgische 
uitdaging en de meeste studies naar anale fistels zijn uitgevoerd om de chirurgische 
behandeling te optimaliseren door nieuwe operatie technieken te ontwikkelen en 
evalueren. Ondanks onze pogingen bleven de genezingspercentages teleurstellend 
en leek het onwaarschijnlijk dat chirurgische behandeling ooit zal leiden tot genezing 
in alle patiënten. Hierop hebben we besloten onze benadering aan te passen. We 
stelden namelijk voor dat een persisterende ontsteking mogelijk een belangrijke rol 
zou kunnen spelen in het recidiveren van anale fistels na de operatie en dat een beter 
begrip van de ziekte uiteindelijk zal helpen bij het ontwikkelen van nieuwe en hopelijk 
succesvollere behandelingen. Daarom is het tweede deel van het proefschrift gericht 
op het beter begrijpen van de pathogenese van anale fistels.
behANdeliNG
De indeling van anale fistels is gebaseerd op het verloop van de fistel ten opzichte van 
de anale kringspieren. Van de vier algemene type anale fistels is de transsfincterische 
fistel de tweede meest voorkomende fistel. Transsfincterische fistels kunnen worden 
geclassificeerd als hoog of laag. Voor veel chirurgen is deze classificatie handig voor 
het selecteren van de optimale behandeling en de keuze tussen een niet kringspier 
sparende operatie (fistulotomie) en een kringspier sparende operatie (TAMVP en LIFT). 
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Hoewel het onderscheidt tussen hoge en lage transsfincterische fistels algemeen 
wordt toegepast, is het onbekend of deze fistels verschillende kenmerken hebben. 
In Hoofstuk 2 zijn de verschillen tussen hoge en lage transsfincterische fistels on-
derzocht. De studie toonde dat lage transsfincterische fistels vaker voorkomen op 
jongere leeftijd (42 versus 47 jaar) en bij vrouwen (43% versus 30%). Verder zijn 
lage transsfincterische fistels overwegend anterieur gelokaliseerd (76 versus 18%) en 
zelden geassocieerd met een abces (4 versus 54%). De interne fistelopening van hoge 
transsfincterische fistels was voornamelijk gelokaliseerd midden posterieur. Het verschil 
in locatie van de interne fistel opening en het geslacht is moeilijk te verklaren omdat 
er geen geslacht specifieke verdeling is van anale klieren. Echter, veronderstellen we 
dat sommige van de lage transsfincterische fistels die bij vrouwen zijn waargenomen 
mogelijk secundair zijn aan een episiotomie. Dit zou mogelijk het verschil in leeftijd en 
geslacht kunnen verklaren. De resultaten van het onderzoek zouden gevolgen kunnen 
hebben voor de kliniek. Bij patiënten met een lage transsfincterische fistel is namelijk 
fistulotomie de behandeling van keuze. Echter is er steeds meer bewijs dat het risico 
op verminderde fecale continentie na fistulotomie veel groter is dan aanvankelijk werd 
aangenomen en in het bijzonder bij vrouwen met een anterieure fistel. Het risico bij 
vrouwen is waarschijnlijk groter, omdat ze een kortere uitwendige kringspier hebben 
die kan beschadigen bij vaginale bevalling. In de studie beschreven in Hoofstuk 2 
zijn bijna de helft van de patiënten met een lage transsfincterische fistel vrouw. Voor 
deze patiënten zou een kringspier sparende operatie, zoals LIFT, mogelijk een betere 
behandeling zijn dan een conventionele fistulotomie.
Fistulotomie is niet geschikt voor patiënten met een hoge transsfincterische fis-
tel en TAMVP wordt beschouwd als de behandeling van keuze voor dit type fistel. 
Aanvankelijk varieerde de gerapporteerde genezingspercentages na TAMVP tussen 
84% en 100%. Echter is duidelijk geworden dat TAMVP onsuccesvol is in één van 
de drie patiënten. Enkele studies toonde aan dat roken, obesitas en eerdere opera-
ties de uitkomst van TAMVP nadelig beïnvloeden, echter werden deze bevindingen 
nooit bevestigd door andere studies. Hierdoor is er nog veel onduidelijkheid welke 
factoren mogelijk invloed hebben op de uitkomst van TAMVP. In Hoofdstuk 3 worden 
zeventien potentiële voorspellers van de uitkomsten van TAMVP onderzocht bij 252 
patiënten met een hoog transsfincterische fistel. De studie toonde aan dat patiënten 
met een hoefijzervormige extensie van de fistel een aanzienlijk betere uitkomst had-
den van de behandeling. Een mogelijke verklaring voor deze onverwachte bevinding 
is dat het traject van de fistel afhankelijk is van de ernst van de ziekte. Hoe ernstiger 
de fistuleuze ziekte, hoe directer de fistel de kringspieren doorkruist. Fistels zonder 
hoefijzervormige extensie zijn daarom lastiger te behandelen.
In eerdere studie van onze onderzoeksgroep werd het effect van een tweede TAMVP 
onderzocht. Tijdens de tweede TAMVP werd vastgesteld dat na de eerst ingreep de 
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flap overal was ingegroeid, behalve op de plaats van de oorspronkelijke inwendige 
opening. Deze opmerkelijke klinische bevinding suggereert dat het persisteren van de 
fistel na TAMVP veroorzaakt zou kunnen worden door het voortduren van het ziekte-
proces in het resterende fistelkanaal. Het resterende fistelkanaal na TAMVP is gelegen 
in de intersfincterische ruimte vlakbij de oorsprong van de fistel. LIFT werd geïntrodu-
ceerd als een aantrekkelijke kringspier sparende operatie door Rojanasakul, die een 
genezingspercentage van 94% beschreef. Op basis van deze veelbelovende resultaten 
suggereerden wij dat LIFT mogelijk het voortdurende ziekteproces in het resterende 
fistelkanaal kan verwijderen en hierdoor de resultaten van TAMVP zou verbeteren. In 
Hoofstuk 4 wordt het effect van een additionele LIFT geëvalueerd op de uitkomst van 
TAMVP bij patiënten met een hoge transsfincterische fistel. Primaire genezing werd 
geobserveerd in 51% van de patiënten. In 29% van de patiënten recidiveerde de hoge 
transsfincterische fistel. In 20% van de patiënten werd een conversie geobserveerd, 
van transsfincterische fistel naar intersfincterische fistel. Daaropvolgend ondergingen 
deze patiënten een fistulectomie, waarbij de inwendige kringspier werd gekliefd. In 
alle patiënten was deze ingreep succesvol, waardoor de totale genezing in de studie 
71% bedroeg. We concludeerden dat een additionele LIFT de uitkomst van TAMVP 
niet verbeterd.
Fistulotomie wordt beschouwd als de behandeling van keuze voor patiënten met 
een lage transsfincterische fistel. Echter zijn er steeds meer aanwijzingen dat het risico 
op verminderde fecale continentie na fistulotomie aanzienlijk is. Vooral vrouwelijke 
patiënten met een anterieure fistel en patiënten met een verminderde kringspier 
functie lopen een groter risico. LIFT werd initieel toegepast bij hoge transsfincterische 
fistels, echter zou deze kringspier sparende procedure ook kunnen worden ingezet bij 
lage transsfincterische fistels. Hoofstuk 5 beschrijft de klinische resultaten van LIFT bij 
patiënt met een lage transsfincterische fistel. Primaire genezing werd geobserveerd in 
82% van de patiënten. In alle patiënten zonder primaire genezing werd een conversie 
van lage transsfincterische fistel naar lage intersfincterische fistel waargenomen. Dit 
verschijnsel doet vermoeden dat LIFT voldoende genezing biedt aan de kant van de 
uitwendige kringspier maar niet altijd voldoende genezing biedt aan de kant van 
de inwendige kringspier en hierdoor leidt tot een aanhoudende ontsteking in het 
intersfincterische vlak. In Hoofstuk 7 toonde we aan dat het intersfincterische fis-
teltraject in de meeste gevallen bekleed is met granulatie weefsel. De aanwezigheid 
van granulatie weefsel is suggestief voor een inflammatoir proces. Conversie naar 
een intersfincterische fistel zou het gevolg kunnen zijn van een aanhoudend inflam-
matoire proces. Door conversie was een tweede ingreep noodzakelijk, waarbij een 
fistulotomie werd uitgevoerd. Dit kan worden beschouwd als een nadeel van de LIFT 
techniek, met een potentieel risico op verminderde fecale continentie. Enkele studies 
toonde verminderde fecale continentie bij 38% van de patiënten. In de huidige studie 
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was de mediane Rockwood Fecale incontinentie Severity Index (RFISI) onveranderd na 
operatie. Wij stellen voor dat LIFT is een goed alternatief voor fistulotomie, echter bij 
sommige patiënten zal een tweede procedure noodzakelijk zijn.
Hoofstuk 6 beschrijft de resultaten van TAMVP gecombineerd met drainage van 
abcessen bij een serie van 14 patiënten met een hoge intersfincterische fistel. In-
tersfincterische fistels met een hoog opwaarts verloop, tot aan of boven het niveau 
van de puborectale spieren, zijn zeldzaam. De meeste van deze fistels hebben geen 
uitwendige opening en worden vaak geassocieerd met een hoge intersfincterische 
en/of supralevatoire abcessen. Het klieven van een groot deel van de inwendige 
kringspier bij een verlengde fistulotomie leidt tot een potentieel risico op verminderde 
fecale continentie. Voor zover bekend zijn er geen studies over kringspier sparende 
behandelingen van deze fistels. In de huidige studie was TAMVP met drainage van 
de abcessen succesvol in 79% van de patiënten. Alleen bij patiënten met een su-
pralevatoir abces werd geen primaire genezing geobserveerd en waren aanvullende 
procedures (inclusief drainage met of zonder TAMVP) noodzakelijk om genezing te 
bereiken. Aangezien endoanale MRI bij 13 patiënten abcessen toonde, adviseren wij 
preoperatieve beeldvorming voor alle hoge intersfincterische fistels. Dit levert namelijk 
essentiële informatie voor de chirurgische ingreep.
PAthoGeNese
Epithelialisatie wordt beschouwd als een belangrijke oorzaak voor het persisteren  van 
anale fistels. Lunniss et al. observeerden epithelialisatie in de meerderheid van de fis-
tels en van Koperen et al. vonden voornamelijk epithelialisatie vlakbij de interne fistel 
opening. Hoewel het effect van epithelialisatie nooit werd onderzocht, suggereerde 
beide studies dat dit mogelijk de oorzaak was voor het persisteren van anale fistels. 
Hoofstuk 7 beschrijft de prevalentie van epithelialisatie in het anale fisteltraject en 
het effect van epithelialisatie op de uitkomst van fistel chirurgie. Epithelialisatie werd 
slechts in 25% van de fisteltrajecten waargenomen en in 75% van de fisteltrajecten 
werd granulatie weefsel aangetoond. Er was geen verschil in uitkomst van fistel chi-
rurgie tussen fistels met of zonder epithelialisatie. Er wordt gesuggereerd dat persiste-
rende inflammatie voorkomt dat myofibroblasten kunnen migreren. Myofibroblasten 
spelen een belangrijke rol in het weefsel herstel proces. Deze cellen zijn in staat om 
een nieuw basaal membraan te vormen, wat een voorwaarde is voor de migratie van 
epitheliale cellen. De afwezigheid van epithelialisatie en aanwezigheid van granulatie 
weefsel in het merendeel van de fisteltrajecten zou een uiting kunnen zijn van een 
persisterende inflammatie.
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Verschillende auteurs beschreven de bacteriologie van anale fistels. Zij toonde 
aan dat er geen sprake was van pathogene bacteriën. Bovendien was er slechts 
sprake van een laag aantal bacteriën, dit suggereert dat permanente infectie geen 
belangrijke bijdragen zou hebben bij het persisteren van fistels. De auteurs paste al-
leen conventionele microbiologische kweektechnieken toe, echter kunnen behalve 
levende bacteriën ook bacteriële resten bijdragen tot een persisterende ontsteking in 
het resterende fisteltraject. In Hoofdstuk 8 werden conventionele microbiologische 
kweektechnieken en 16S rRNA gene sequencing toegepast voor het observeren 
van bacteriën en immunohistochemie werd toegepast voor het aantonen van pro-
inflammatoire bacteriële peptidoglycanen (PG). Studies naar de pathogenese van 
verschillende chronische ontstekingsziekten, zoals de ziekte van Crohn, tonen aan 
dat PG een krachtige stimulator is voor ontsteking. Uit onze studie bleek dat fistels 
niet gekoloniseerd waren met pathogene bacteriën en het aantal aanwezige bacte-
riën zeer klein was. Daarom lijkt het onwaarschijnlijk dat een bacteriële infectie een 
belangrijke rol speelt bij het persisteren van fistels. Deze resultaten werden onlangs 
bevestigd door Tozer et al.. In tegenstelling tot de bevindingen van conventionele 
microbiologische kweektechnieken en 16S rRNA gene sequencing, observeerden we 
wel pro-inflammatoire PG in de meeste fistels. PG heeft krachtige pro-inflammatoire 
eigenschappen en stimuleert de verwerking en secretie van cytokine interleukine (IL)-
1β. Dit suggereert dat zelfs in afwezigheid van lokale bacteriële replicatie, bacteriële 
resten ontsteking kunnen bevorderen.
Cytokinen, zoals IL-1β, spelen een belangrijke rol bij ontsteking. Veel biologicals, 
gericht op cytokinen en hun receptoren, zijn beschikbaar voor de behandeling van 
een breed scala van inflammatoire ziekten. Detectie en identificatie van cytokinen in 
anale fistels kunnen daarom implicaties hebben voor toekomstige behandelingen. Om 
deze reden hebben we de aanwezigheid van een geselecteerd panel van cytokinen, 
zoals pro-inflammatoire IL-1β en tumornecrosefactor α (TNF-α), onderzocht in anale 
fistels. De resultaten zijn beschreven in Hoofdstuk 9. De belangrijkste bevinding van 
deze studie was de overvloedige expressie van IL-1β in 93% van de anale fistels. Ook 
cytokinen IL-8, IL-12p40 en TNF-α waren aanwezig in respectievelijk 70%, 33% en 
30% van de fistels. We suggereren dat additionele behandeling van anale fistels ge-
richt op cytokinen mogelijk gunstig kan zijn en stellen voor dat dit verder onderzocht 
moeten worden.
toekomstPersPectieveN
Het doel van moderne anale fistel behandelingen is genezing van de fistel zonder 
verminderde fecale continentie. Kringspier sparende behandelingen zijn ontwikkeld 
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voor anale fistels, waarvoor fistulotomie ongewenst is. Behandeling van deze typen 
fistels blijft moeilijk en enigszins teleurstellend. Ondanks onze inspanningen lijkt het 
er namelijk op dat chirurgische behandeling op zichzelf nooit zal leiden tot volledige 
genezing van alle fistels. We suggereren dat inflammatie een rol speelt. In Hoofstuk 9 
observeerden we de overvloedige expressie van het pro-inflammatoire cytokine IL-1β. 
Cytokinen spelen een belangrijke rol bij ontsteking en verhoogde expressie van IL-1β 
wordt waargenomen bij ziekten, zoals hidradenitis suppurativa. Momenteel zijn er 
drie IL-1 antagonisten gericht op IL-1β goedgekeurd voor de behandeling van diverse 
ziekten en onderzoek naar nieuwe toepassingen vindt plaats. De behandeling van 
anale fistels zal mogelijk veranderen, waarbij chirurgie wordt gecombineerd met de 
behandeling van ontsteking. Voorstellen voor toekomstig onderzoek en behandeling:
- Onderzoek naar willekeurige behandelingsopties voor anale fistels moet stoppen. 
We zullen eerst de ziekte moeten begrijpen voordat we het kunnen behandelen.
- Toekomstig onderzoek moet zich meer richten op de etiologie en pathogenese van 
anale fistels. De huidige literatuur hierover is namelijk beperkt. Bovendien zou dit 
kunnen leiden tot nieuwe (additionele) behandelingsopties.
- Kringspier sparende operaties zullen op zichzelf nooit leiden tot volledige gene-
zing van alle anale fistels. Waarschijnlijk zullen deze procedures gecombineerd 
moeten worden met additionele behandeling van de inflammatie in de fistel om 
de genezingskans te verbeteren. Dit behoeft nader onderzoek.
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